Blood in healthy organisms is seen as a ‘sterile’ environment: it lacks proliferating microbes. Dormant or not-immediately-culturable forms are not absent, however, as intracellular dormancy is well established. We highlight here that a great many pathogens can survive in blood and inside erythrocytes. ‘Non-culturability’, reflected by discrepancies between plate counts and total counts, is commonplace in environmental microbiology. It is overcome by improved culturing methods, and we asked how common this would be in blood. A number of recent, sequence-based and ultramicroscopic studies have uncovered an authentic blood microbiome in a number of non-communicable diseases. The chief origin of these microbes is the gut microbiome (especially when it shifts composition to a pathogenic state, known as ‘dysbiosis’). Another source is microbes translocated from the oral cavity. ‘Dysbiosis’ is also used to describe translocation of cells into blood or other tissues. To avoid ambiguity, we here use the term ‘atopobiosis’ for microbes that appear in places other than their normal location. Atopobiosis may contribute to the dynamics of a variety of inflammatory diseases. Overall, it seems that many more chronic, non-communicable, inflammatory diseases may have a microbial component than are presently considered, and may be treatable using bactericidal antibiotics or vaccines.

INTRODUCTION

‘Overall, it seems inevitable that the availability of these methods will cause the catalog of disease states recognized as having a microbial contribution to their etiology to expand enormously in the short term, particularly as improved methods for resuscitation of small cell numbers are found’ (Davey and Kell 1996).

Over the years, a variety of diseases that were previously considered non-communicable have been found to have a microbial component, the role of Helicobacter pylori in ulcerogenesis (Marshall and Warren 1984) being a particularly well-known example. There have also been hints for a microbial component to many other non-communicable diseases, but culturing the relevant organisms has rarely been successful. However, there is increasing recognition that microbes may be present in forms that are not easily culturable, and a number of recent articles have brought these possibilities more sharply into focus. Our aim is to review these developments. The manuscript structure is shown in Fig. 1.

An overview figure summarizing the contents of this manuscript.
Figure 1.

An overview figure summarizing the contents of this manuscript.

A note on terminology: viable, culturable, dormant and sterile

In this field, much confusion has arisen historically because of a failure to recognize that most microbes reproduce by binary fission and that this reproduction must be a minimal property or hallmark of a microbial cell that possesses ‘life’ or is ‘alive’ (Proal, Albert and Marshall 2011). Thus, as with Schrödinger's cat (e.g. Primas 1981; Gribbin 1985), we cannot say that an individual microbial cell ‘is’ alive, only (if true) that it ‘was’ alive, since it will by then have become two cells. This implies that being alive is not best treated as though it were an innate property of a cell, but the definition must be operational, and include both the cell and the ‘environment’ (experiment) used to detect the status a posteriori (Kell et al.1998).

Thus, as with Postgate (e.g. Postgate 1967, 1969, 1976), we equate viability with culturability, and stress that culturability—the ability to reproduce—is to be determined operationally. Other methods that do not determine culturability are not tests of viability per se, but merely measure what they measure (e.g. the content of a chemical such as ATP, membrane permeability to a dye, enzymatic activity, macromolecular sequences and so on). In addition, it is impossible in principle to (cor)relate macroscopic measurements of a culture with the ability of individual cells to divide (Kell et al.1991; Davey and Kell 1996). In other words, if the macroscopic ATP content of say a starving culture were to decrease by 50%, we would not know if all of the cells had lost half their ATP or half of the cells had lost all of their ATP (or anything in between). The culturability of the former would likely be 50% and of the latter 100%, despite the same macroscopic ATP content.

A lack of culturability may mean that a cell is non-viable under the circumstances tested, but viability or non-viability are not the only two possible states here. An apparent non-culturability of a surviving cell also admits another possibility, for which the natural term is ‘dormant’ (Kaprelyants, Gottschal and Kell 1993; Epstein 2013). This is that the cell is not presently culturable (viable), but it is not ‘dead’ (in the sense of an operationally irreversible loss of viability) in that it may be induced to return to a state of culturability (by a process or processes typically referred to as ‘resuscitation’). This also means that the term ‘viable-but-non-culturable’, while quite common in use, is in fact an oxymoron that is to be discouraged (Kell et al.1998). The eminent microbial physiologist Howard Gest is similarly scathing about the term ‘unculturable’ (Gest 2008), noting that one just needs to try harder to culture organisms. Table 1 shows the three terms best suited to discuss these issues, while Fig. 2 shows a diagrammatic representation of the macroscopic physiological microbial states we mostly consider.

A diagrammatic representation of the major macroscopic physiological states of microbes and their interrelationships.
Figure 2.

A diagrammatic representation of the major macroscopic physiological states of microbes and their interrelationships.

Table 1.

Operational definitions of viable, non-viable and dormant microbes. These are the three terms we consider best suited to describe the macroscopic physiological states of microbes as regards their ability to replicate. We note that the terms ‘not immediately culturable’ (NIC) and ‘active but not culturable’ (ABNC) can also have some utility (Kell et al.1998), while dormant cells are sometimes referred to as ‘persisters’. Other variants of ‘dormancy’ that have been used include ‘anabiosis’ (Keilin 1959) and ‘cryptobiosis’ (e.g. Clegg 2001; Neuman 2006); all these terms imply a reversible state between the appearance of being living and non-living in different circumstances. This definition of dormancy also likely includes cells that may operationally be ‘injured’, and possibly wall-less L-forms (Domingue and Woody 1997; Mattman 2001; Allan, Hoischen and Gumpert 2009; Domínguez-Cuevas et al.2012; Errington 2013; Mercier, Kawai and Errington 2013, 2014) provided they are or may become culturable. ‘Sterile’ refers to an absence of operationally viable organisms as defined in this table.

TermProperties
ViableCapable of observable replication, i.e. culturable, by any stated means.
Non-viableIncapable of observable replication by any stated means normally capable of effecting replication in the relevant organism.
DormantNot viable in the sense of not being more or less immediately culturable, but may be returned to a state of viability or culturability by preincubation under suitable conditions.
TermProperties
ViableCapable of observable replication, i.e. culturable, by any stated means.
Non-viableIncapable of observable replication by any stated means normally capable of effecting replication in the relevant organism.
DormantNot viable in the sense of not being more or less immediately culturable, but may be returned to a state of viability or culturability by preincubation under suitable conditions.
Table 1.

Operational definitions of viable, non-viable and dormant microbes. These are the three terms we consider best suited to describe the macroscopic physiological states of microbes as regards their ability to replicate. We note that the terms ‘not immediately culturable’ (NIC) and ‘active but not culturable’ (ABNC) can also have some utility (Kell et al.1998), while dormant cells are sometimes referred to as ‘persisters’. Other variants of ‘dormancy’ that have been used include ‘anabiosis’ (Keilin 1959) and ‘cryptobiosis’ (e.g. Clegg 2001; Neuman 2006); all these terms imply a reversible state between the appearance of being living and non-living in different circumstances. This definition of dormancy also likely includes cells that may operationally be ‘injured’, and possibly wall-less L-forms (Domingue and Woody 1997; Mattman 2001; Allan, Hoischen and Gumpert 2009; Domínguez-Cuevas et al.2012; Errington 2013; Mercier, Kawai and Errington 2013, 2014) provided they are or may become culturable. ‘Sterile’ refers to an absence of operationally viable organisms as defined in this table.

TermProperties
ViableCapable of observable replication, i.e. culturable, by any stated means.
Non-viableIncapable of observable replication by any stated means normally capable of effecting replication in the relevant organism.
DormantNot viable in the sense of not being more or less immediately culturable, but may be returned to a state of viability or culturability by preincubation under suitable conditions.
TermProperties
ViableCapable of observable replication, i.e. culturable, by any stated means.
Non-viableIncapable of observable replication by any stated means normally capable of effecting replication in the relevant organism.
DormantNot viable in the sense of not being more or less immediately culturable, but may be returned to a state of viability or culturability by preincubation under suitable conditions.

The assessment of replication potential (culturability) of individual cells may be done microscopically (e.g. by microscopic counts) or macroscopically (e.g. via colony formation on an agar plate or through the ‘most probable number’ technique). The latter has the advantage of potentially assessing dormancy in the absence of any contaminating culturable cells that might proliferate during the assay (Kaprelyants, Mukamolova and Kell 1994; Votyakova, Kaprelyants and Kell 1994; Kell et al.1998). For assessing culturability (=viability), we do not therefore include other strategies in which cells do not actually divide, such as the so-called direct viable count of Kogure, Simidu and Taga (1979). Thus, we here highlight the point that the possibility of microbial dormancy means that a system that appears to be devoid of culturable microbes may still contain dormant cells or forms that may become culturable.

The ‘sterile’ blood microbiome brought into question

The circulation is a closed system and the blood in healthy organisms was first believed to be a sterile environment (Drennan 1942; Proal, Albert and Marshall 2014). This definition is used in the most usual sense of an absence of culturable microbes, since blood can of course provide a suitable growth medium for microbes (as in blood culture; Wilson and Weinstein 1994; Weinstein 1996; Schroeter et al.2012; cf. Valencia-Shelton and Loeffelholz 2014), and any bacteraemia or sepsis, even at 1–10 cells mL−1 (Murray 2015), is potentially life-threatening (e.g. Vincent et al.2009; Eleftheriadis et al.2011; Havey, Fowler and Daneman 2011; Montassier et al.2013). However, the principle of the presence of truly sterile blood in healthy humans has been challenged, as operationally it does not mean that dormant or non-culturable forms of organisms are absent (Kaprelyants, Gottschal and Kell 1993; Kell et al.1998; McLaughlin et al.2002) (see Table 1). Nearly 50 years ago, the existence of a novel bacteriological system was noted in 71% of blood samples taken from diseased humans and from 7% of supposedly healthy humans, when RBCs were lysed (Domingue and Schlegel 1977). A year later, corynebacteria-like microorganisms developing in hemocultures were shown within RBCs (Tedeschi et al.1978), and in 2001 it was found that even ‘healthy’ blood specimens can contain bacterial 16S ribosomal DNA (Nikkari et al.2001). Domingue and Woody (1997) and Domingue (2010) summarizes much of this earlier literature. L-forms are bacterial variants that lack some or all of a cell wall. Nonetheless they can divide, especially in osmotically stabilized media, by processes that variously involve membrane blebbing, tubulation, vesiculation and fission (Allan, Hoischen and Gumpert 2009; Errington 2013; Mercier, Kawai and Errington 2014). While it remains unclear whether what was seen in these earlier studies (Domingue and Woody 1997; Domingue 2010) may have been L-forms (Mattman 2001), that could in time revert to normal bacteria under the correct conditions (Casadesús 2007), L-forms are becoming a topic of considerable current research (Devine 2012; Domínguez-Cuevas et al.2012; Mercier, Kawai and Errington 2013, 2014).

The presence of a blood bacterial microbiome has also been associated with a variety of infectious, as well as non-infectious disease states (Huang et al.2006; Thwaites and Gant 2011; Nielsen et al.2012; Prajsnar et al.2012; Wang et al.2012a; Kibru et al.2014; Sato et al.2014). It is, for example, known that H. pylori can exist not only in the gastric mucosa but also in peripheral blood, where it could cause bacteremia (Huang et al.2006), and could contribute to Parkinson's disease (PD) or related pathologies that precede motor symptoms (Nielsen et al.2012). Helicobacter pylori was also previously implicated in the development of anemia (Wang et al.2012b; Kibru et al.2014). Staphylococcus aureus can also use neutrophils as ‘Trojan horses’ to disseminate infection (Thwaites and Gant 2011; Prajsnar et al.2012), while many other pathogens, such as Listeria monocytogenes (Xayarath and Freitag 2012), Salmonella typhimurium (Eisenreich et al.2010; Claudi et al.2014; Holden 2015) and Yersinia pestis (Isberg 1991), are well known to persist intracellularly; Gest (2008) gives other historical examples. The same is true for viruses, which are not discussed here.

The presence of an aberrant blood microbiota (as assessed by sequencing) has been implicated in type II diabetes and cardiovascular disease (Amar et al.2011, 2013; Sato et al.2014). There is also growing evidence that periodontal disease and gingivitis are closely linked to cardiovascular disease (Yang et al.2013; Ramírez et al.2014). Oral bacterial translocation into the blood has been implicated in the development of periodontal disease-induced endocarditis and myocardial and/or cerebral infarction, especially in patients with heart valve dysfunction (Koren et al.2011; Amar and Engelke 2014; Seringec et al.2014).

We will argue in the next sections that the existence of potentially viable (but possibly non-proliferating) pleomorphic bacteria in the blood of healthy humans (McLaughlin et al.2002) may therefore be of some significance in pathology. If such a microbiome can disrupt homeostasis, it can ultimately play a fundamental role in disease development and progression. It has therefore been proposed that the blood microbiota might therefore represent or contribute to the first step in the kinetics of atherosclerosis (Sato et al.2014), cardiovascular disease and type II diabetes (Amar et al.2011), and therefore ultimately serve as biomarkers for cardiovascular disease risk (Amar et al.2013). However, in the quest to use the blood microbiota as biomarkers, the question of detectability and cultivability are key concepts.

In particular, the existence of a blood microbiome is only really meaningful and of scientific interest if it represents an undisturbed state, and is not, for instance, an artefact caused by the external introduction of microbes through human intervention, reagent contamination (Schroeter et al.2012; Salter et al.2014) and so forth. We therefore rehearse the evidence that while such artefacts are certainly possible, and must be excluded rigorously, the phenomenon of a human blood microbiome cannot be dismissed as such an artefact in toto.

Evidence that these observations are not due to contamination

While contamination from reagents (e.g. Schroeter et al.2012; Salter et al.2014), or simply poor sterile technique with needles and so on, can lead to an artefactual appearance of a blood microbiome, we consider that the following arguments, taken together, exclude the thought that the entire (and considerable) literature on a blood microbiome can be explained via contamination.

  • The first argument is that there are significant differences between the blood microbiomes of individuals harboring disease states and nominally healthy controls, despite the fact that samples are treated identically (see later). Some similar arguments apply to the assessment of drug transporters under different conditions (Kell and Oliver 2014).

  • A second argument is that the morphological type of organism (e.g. coccus versus bacillus) seems to be characteristic of particular diseases.

  • A third argument is that in many cases (see below) relevant organisms lurk intracellularly, which is hard to explain by contamination.

  • A fourth argument is that there are just too many diseases where bacteria have been found to play a role in the pathogenesis, that all of them may be caused by contamination.

  • Finally, the actual numbers of cells involved seem far too great to be explicable by contamination; given that blood contains more than 109 erythrocytes mL−1, if there was just one bacterial cell per 100 000 erythrocytes (see below and Amar et al.2011), this will equate to 104 bacteria mL−1. These are not small numbers.

It is important to point out that molecular methods have been used frequently to detect active sepsis. These selfsame methods are also used in environmental biology (as we pointed out in this review), without undue concern about the potential for contamination. Contamination will always be a concern, of course, as noted by Nikkari et al. (2001), but many papers since 2001 have documented strategies for detecting prokaryotic DNA in blood and serum using appropriate and careful controls (Anthony et al.2000; Mylotte and Tayara 2000; Jiang et al.2009; Varani et al.2009; Mancini et al.2010; Chang et al.2011; Grif et al.2012a; Fernández-Cruz et al.2013; Gaibani et al.2013). Also, detecting bacteria in blood cultures during sepsis is considered the standard diagnostic tool for blood stream infections (Muñoz et al.2008; Varani et al.2009), and some laboratories consider that e.g. PCR testing should always be a complement for the traditional blood culture test (Grif et al.2012b).

The role of dormancy

Dormancy in microbiology is of course well known, even for non-sporulating bacteria, and has been defined as a stable but reversible nonreplicating state (Mariotti et al.2013; see also Table 1 and Kaprelyants, Gottschal and Kell 1993; Kell et al.1998, 2003). The importance of dormant or non-cultured (as opposed to ‘non-culturable’) organisms has long been recognized in environmental microbiology (e.g. Mason, Hamer and Bryers 1986; Amann, Ludwig and Schleifer 1995; Eilers et al.2000; Hugenholtz 2002; Keller and Zengler 2004; Pham and Kim 2012; Epstein 2013), because of the 100-fold or greater difference between microscopically observable cells and those capable of forming a colony on an agar plate (‘the great plate count anomaly’, see below).

Of the four main possibilities, what we do not know in general is whether the ‘missing’ cells

  • are incapable of growth on the enrichment/isolation media,

  • are killed by the enrichment/isolation media (e.g. Tanaka et al.2014),

  • have lost viability irreversibly (i.e. are operationally dead) or

  • are in a dormant or not-immediately-culturable state from which we might resuscitate them (to effect culturability) if only we knew how.

The fact that typical isolation media and incubation conditions do not admit the measurable growth of all strains is certainly well known (indeed it is the basis for selective isolation media!), and it took a good while to learn how to culture pathogens such as H. pylori (Marshall and Warren 1984; Marshall 2006), Legionella pneumophila (Feeley et al.1978; Saito et al.1981; Meyer 1983), Tropheryma whipplei (Maiwald and Relman 2001; Maiwald et al.2003; Renesto et al.2003) and so on (Singh et al.2013). The majority of bacteria that persist in a ‘non-culturable’ form in wounds (e.g. Dowd et al.2008; Percival et al.2012), or in diseases such as cystic fibrosis (Lewis 2010) or tuberculosis (Young, Stark and Kirschner 2008; Zhang, Yew and Barer 2012), and even simply in conventional cultures of Escherichia coli (e.g. Koch 1987; Balaban et al.2004; Keren et al.2004a,b; Gerdes and Maisonneuve 2012; Amato, Orman and Brynildsen 2013; Germain et al.2013; Maisonneuve, Castro-Camargo and Gerdes 2013; Maisonneuve and Gerdes 2014; Holden 2015), where phenotypic culture differentiation is well established (Koch 1971), are also ‘normally culturable’ by established means. Thus, the existence of operationally ‘non-culturable’ forms of only moderately fastidious bacteria is very well established, and more and more bacteria previously thought ‘unculturable’ are being brought into culture (e.g. Zengler et al.2002; Keller and Zengler 2004; Stevenson et al.2004; Gich et al.2005; Kamagata and Tamaki 2005; D'Onofrio et al.2010; Nichols et al.2010; Vartoukian, Palmer and Wade 2010; Dedysh 2011; Pham and Kim 2012; Puspita et al.2012, 2013; Stewart 2012; Allen-Vercoe 2013; Narihiro and Kamagata 2013; Singh et al.2013; Walker et al.2014; Lagier et al.2015a,b; Ling et al.2015).

In environmental microbiology, some bacteria pass through the usual 0.2 μm filters, and have been referred to as ‘ultramicrobacteria’ (Macdonell and Hood 1982; Morita 1997). It was proposed (Kaprelyants, Gottschal and Kell 1993) that rather than being small (starved) forms of normal bacteria they were more likely to be normal forms of small bacteria, and this seems to have been accepted (Lysak et al.2010; Sahin et al.2010; Duda et al.2012; Soina et al.2012).

The ability to culture certain kinds of soil bacteria by preincubation in weak broth is also well established (e.g. Bakken and Olsen 1987; Kaprelyants, Gottschal and Kell 1993), and our own experiments showed very high levels of resuscitability of dormant cells of Micrococcus luteus (e.g. Kaprelyants and Kell 1993; Kaprelyants, Mukamolova and Kell 1994; Kaprelyants et al.1996, 1999; Kell et al.1998, 2003; Mukamolova et al.1998a,b, 1999, 2002a,b). In a similar way, substrate-accelerated death of non- or slowly growing microorganisms has been known for decades (Postgate 1967; Calcott and Postgate 1972; Calcott and Calvert 1981).

Thus, any of several well-established mechanisms may contribute to the (often) large differences observable between microscopic counts and the number of operationally culturable microbes, with the greatest likelihood being that we simply have to develop more and better methods to bring these strains back into culture, i.e. to resuscitate them. In particular, however, this ‘great plate count anomaly’ has, of course, been brought into much sharper focus because of the advent of culture-independent, sequence-based means for detecting and (to a certain extent) enumerating microbes (though not, of course, of assessing their culturability).

Sequence-based methods for detecting non-proliferating microbes

The vast majority of microbial species remain uncultivated and, until recently, about half of all known bacterial phyla were identified only from their 16S ribosomal RNA gene sequence (Lasken and McLean 2014). Also, single-cell genomics is a powerful tool for accessing genetic information from uncultivated microorganisms (Lasken 2012; Rinke et al.2013; Cavanagh et al.2014; Clingenpeel et al.2014). Bacterial single-cell genome sequencing and bioinformatics are, however, challenging (Pallen, Loman and Penn 2010; Didelot et al.2012; Loman et al.2012; Fricke and Rasko 2014).

The development of sequence-based methods for microbes (and especially non-eukaryotes) owes much to the pioneering work of Carl Woese and colleagues, who recognized the utility of small subunit ribosomal RNA (based on both its essentiality and the small but significant sequence variations) and applied it with great effect in molecular phylogenetics (Woese and Fox 1977; Woese, Kandler and Wheelis 1990). Notwithstanding modern reinterpretations of the taxonomic details derived therefrom (e.g. Williams et al.2013), there can be little doubt that this work drew the attention of microbiologists to the potential of sequence-based methods for detecting microbes that were then invisible to methods based solely on culture, e.g. in clinical microbiology (Didelot et al.2012; Loman et al.2012; Proal et al.2013; Fricke and Rasko 2014). rRNA remains a widely used strategy for detecting specific microbes. This has of course led to metagenomics, the large-scale sequencing of macromolecules and indeed (statistically) entire genomes from complex (non-axenic) environments, increasing the requirement for a full set of complete reference sequences (Kyrpides et al.2014) and not just those of 16S rRNA (Yarza et al.2013). Even the coupling of sequences to activities has now become possible (e.g. Radajewski et al.2000; Wang et al.2012c).

Microbiome analyses: latest technologies employed

More recently, gut metagenomics has been systematized with NIH's Human Microbiome project (HMP) and the European MetaHIT project aiming to deciphering the structure and function of the human gut microbiota (Fredricks 2013; Robles-Alonso and Guarner 2014). The HMP has developed a reference collection of 16S ribosomal RNA gene sequences collected from sites across the human body (Koren et al.2013; Ding and Schloss 2014). This information can be used to associate changes in the microbiome with changes in health, and particularly also the blood microbiome. The Integrative Human Microbiome Project (iHMP, http://hmp2.org), the second phase of the NIH HMP, aims to study the interactions by analyzing microbiome and host activities in longitudinal studies of disease-specific cohorts and by creating integrated data sets of microbiome and host functional properties (The Integrative HMP (iHMP) Research Network Consortium 2014), ultimately allowing us to analyze host and microbial DNA (genome) and RNA (transcriptome) sequences (Morgan and Huttenhower 2014). However, in the HMP study, the main anatomic sites where samples are collected are skin, mouth, nose, colon and vagina (ElRakaiby et al.2014). So far as we are aware, these projects do not focus on the blood microbiome (which is probably unsurprising when most commentators assume that it does not exist).

The gut microbiome is by far the largest numerically, and our purpose here is not to review it in any detail, since this has been done very well in terms of

  • its constitution (Lozupone et al.2012; Weinstock 2012),

  • temporal variation (Caporaso et al.2011; Flores et al.2014; Thaiss et al.2014),

  • changes associated with diet (Muegge et al.2011),

  • obesity (Turnbaugh et al.2006, 2009),

  • age and geography (Delzenne and Cani 2011; Delzenne et al.2011; Yatsunenko et al.2012),

  • inflammation (Cani et al.2008, 2012),

  • the immune system (Kau et al.2011; McDermott and Huffnagle 2014)

  • and various pathologies (Pflughoeft and Versalovic 2012; Schulz et al.2014).

It was implied that a better understanding of microbiome-encoded pathways for xenobiotic metabolism might also have implications for improving the efficacy of pharmacologic interventions with neuromodulatory agents (Gonzalez et al.2011), and that the exploration of microbiome and metagenome might give us insightful new perspectives regarding human genetics and how the microbiota contribute to immunity, as well as to metabolic and inflammatory diseases (Cho and Blaser 2012; Blaser et al.2013; Blaser 2014; Leslie and Young 2015). This is because it is assumed in such studies that it is the small-molecule products of the gut microbiome that can appear in the human serum metabolome, and thus influence the rest of the human body (e.g. Wikoff et al.2009; Holmes et al.2011; Le Chatelier et al.2013, and see Table 2). Here we also need to mention lipopolysaccharide (LPS), a main constituent of the Gram-negative outer membrane that induces the production of cytokines and/or chemokines, which in turn regulate inflammatory and innate and subsequent adaptive immune responses (Glaros et al.2013; Rhee 2014; Ronco 2014). The release of LPS may therefore change gut homeostasis, may play a role in e.g. inflammatory bowel disease and necrotizing enterocolitis (Rhee 2014), and may certainly act as an acute phase protein in sepsis (Ding and Jin 2014).

Table 2.

Some examples of small molecule gut metabolites whose secretion has been implicated in various disease states.

MetaboliteIntermediates/productsSynthesisRole in health and diseaseReferences
Amino acidsThe gut microbiota is not itself an important source of amino acids during periods of adequate protein intake. Some commensal members produce biologically active components from amino acids. Amino acid supplementation in a mouse model of ulcerative colitis has been shown to promote overall growth of commensal microbiota. The effect was considered to be mediated via the stimulatory effect on mucin production by amino acid supplementation.Faure et al. (2006); Devaraj, Hemarajata and Versalovic (2013); Bergen (2014)
BenzoatesBenzoic acid, hippurate, 2-hydroxyhippurateGut microbiota in mice with active colitis displayed enrichment for genes involved in benzoate degradation. Hippurate derives from plant food polyphenols and is a conjugate of benzoic acid with glycine. In humans a large portion of hippurate is believed to be derived from precursors absorbed in the small intestines. It is reliably decreased in IBD.Rechner et al. (2002); Aronov et al. (2011); De Preter and Verbeke (2013); Rooks et al. (2014)
Bile acidsBile acids are synthesized from cholesterol in the liver and further metabolized into secondary bile acids by the gut microbiota. The amino acid sides chain of glyco- and tauro-conjugated bile acids are cleaved by bacterial bile salt hydrolase (BSH) enzyme to yield unconjugated bile acids (cholic and chenodeoxycholic acids). These products will then be further modified by gut bacteria to produce secondary bile acids. A decrease in this conversion is positively correlated with liver cirrhosis. Bile acids can modulate the composition of the microbiota in the gut, where they function as signaling molecules and may constitute a mechanism of quorum sensing. In turn, the microbiota strongly affect bile acid metabolism by promoting deconjugation, dehydrogenation and dehydroxylation. It can also inhibit bile acid synthesis in the liver by alleviation of farnesoid X receptor inhibition in the ileum. Bile acids can induce FMO3 expression by an FXR-dependent mechanism.Martin et al. (2007); Bennett et al. (2013); Gérard (2013); Kakiyama et al. (2013); Martínez et al. (2013); Sayin et al. (2013); Joyce et al. (2014)
LipidsCholesterolThe gut microbiota impact on the host systemic lipid metabolism. When administered as probiotics Bifidobacteria and Lactobacillus can enhance dyslipidemia and insulin resistance. Microbiota have an influence on cholesterol metabolism and weight gain in the host via the bacterial BSH mechanism.Martin et al. (2007); Martínez et al. (2009, 2013); Yu et al. (2013); Joyce et al. (2014)
Methylamines and products of choline metabolismMethylamine, dimethylamine, dimethylglycine, trimethylamine (TMA) and trimethylamine N-oxide (TMAO)Cleavage of choline and phosphatidylcholine (PC) by the gut microbiota via the enzyme choline TMA-lyase produces TMA. Oxidation of TMA by hepatic flavin-containing monooxygenase 3 (FMO3) forms TMAO. Microbial metabolism of L-carnitine also produces TMA via a novel Rieske-type protein. Risk for major adverse cardiovascular events coincides with higher levels of TMAO.Wang et al. (2011); Craciun and Balskus (2012); Koeth et al. (2013); Tang et al. (2013); Zhu et al. (2014)
NeurotransmittersSerotonin, melatonin, glutamate, GABA, noradrenaline, dopamine and acetylcholineIt was recently discovered that gut microbiota produce tryptophan decarboxylase, the enzyme responsible for decarboxylasing tryptophan to tryptamine. Tryptamine promotes the release of serotonin by enterochromaffin cells. In a rat model it was shown that Bifidobacteria treatment resulted in increased tryptophan and kynurenic acid levels. Another study in mice showed the potential of Lactobacillus rhamnosus to modulate the GABAergic system. Decreased levels of dopamine were measured in fecal samples from active colitis mice.Desbonnet et al. (2008); Bravo et al. (2011); Rooks et al. (2014); Williams et al. (2014); O'Mahony et al. (2015)
Phytochemicals, particularly polyphenolic compoundsChlorogenic acids, hydrolysable tannins and flavonoidsA significant amount of polyphenols reaches the colon and is believed to contribute to gut health by promoting the growth of some commensals. Polyphenolic bioconversion by microbiota is paramount in the production of a large range of bioactive molecules. The exact roles of these molecules in health and disease are yet to be fully understood. Nonetheless epidemiological studies have tied polyphenols to health benefits such as antioxidative, anticarinogenic, antiadipogenic, antidiabetic and neuroprotective properties. Gut microbiota can also convert dietary polyphenols to benzoate.Tomas-Barberan et al. (2014); Kahle et al. (2006); Aronov et al. (2011); van Duynhoven et al. (2011); Cardona et al. (2013); Marín et al. (2015)
Polyunsaturated fatty acids (PUFA)Omega 3 and 6L. plantarum has genes encoding for the enzyme involved in saturation metabolism of PUFA.Kishino et al. (2013)
Short-chain fatty acids (SCFAs)Most abundant acetate, propionate, butyrate; to a lesser extent—formate, fumarate, malonate, succinate, caproate and valerateThe SCFAs are produced from bacterial fermentation of non-digestible polysaccharides. They play a role in metabolic syndrome prevention and treatment. Evidence point to their potential to promote metabolic control in type 2 diabetes. SCFAs are a major source of energy for colonocytes and also contribute up to 10% of the host's daily caloric requirements. They are further involved in the control of energy utilization and maintenance of metabolic homeostasis via the G Protein coupled Receptor 43 (GPR43) receptor. SCFA products also dampen inflammatory response through this receptor. SCFAs have also been shown to affect cell proliferation and apoptosis (in cancer cells), and in epigenetic machinery such as histone acetylation by butyrate.Bergman (1990); Maslowski et al. (2009); den Besten et al. (2013); Kimura et al. (2013); Natarajan and Pluznick (2014); Puddu et al. (2014)
VitaminsB-group vitamins, vitamin B12; vitamin C, biotin, vitamin KIt is well established that the gut microbiota synthesize a large number of vitamins de novo. This is important since humans lack biosynthetic pathways for vitamins. The deleterious effects of vitamin deficiencies are well known. It has only recently been suggested that vitamin B12 may also contribute to shaping the structure and function of microbial communities in the human gut.Hill (1997); Cooke, Behan and Costello (2006); Arumugam et al. (2011); LeBlanc et al. (2013); Degnan, Taga and Goodman (2014)
Other noteworthy bioactives
Conjugated linoleic acid (CLA), bacteriocinCLA is associated with a diverse array of biological activities, and predominantly associated with activation of peroxisome proliferator activated receptors (PPARs) and the associated switching on and off of genes. Some Bifidobacteria and Lactobacillus species have been shown to produce CLA. Bacteriocins are peptides synthesized by bacteria and have narrow (same species) or broad (across genera) spectrum activity against other bacteria. A large number of archaea and bacteria are believed to produce at least one bacteriocin.Bowdish, Davidson and Hancock (2005); Ross et al. (2010)
Tetrathionate and nitric oxideTetrathionate and nitric oxide are produced in an inflammatory environment and are central to the fitness of several Enterobacteriaceae. Tetrathionate utilization positively correlated with active colitis in a mouse model. Bacterial growth depends on the presence of nitrogen. Synthesis of amino acids by the microbiome depends on the recycling of nitrogen back into gastrointestinal organs.Winter et al. (2010); Bergen (2014); Rooks et al. (2014)
MetaboliteIntermediates/productsSynthesisRole in health and diseaseReferences
Amino acidsThe gut microbiota is not itself an important source of amino acids during periods of adequate protein intake. Some commensal members produce biologically active components from amino acids. Amino acid supplementation in a mouse model of ulcerative colitis has been shown to promote overall growth of commensal microbiota. The effect was considered to be mediated via the stimulatory effect on mucin production by amino acid supplementation.Faure et al. (2006); Devaraj, Hemarajata and Versalovic (2013); Bergen (2014)
BenzoatesBenzoic acid, hippurate, 2-hydroxyhippurateGut microbiota in mice with active colitis displayed enrichment for genes involved in benzoate degradation. Hippurate derives from plant food polyphenols and is a conjugate of benzoic acid with glycine. In humans a large portion of hippurate is believed to be derived from precursors absorbed in the small intestines. It is reliably decreased in IBD.Rechner et al. (2002); Aronov et al. (2011); De Preter and Verbeke (2013); Rooks et al. (2014)
Bile acidsBile acids are synthesized from cholesterol in the liver and further metabolized into secondary bile acids by the gut microbiota. The amino acid sides chain of glyco- and tauro-conjugated bile acids are cleaved by bacterial bile salt hydrolase (BSH) enzyme to yield unconjugated bile acids (cholic and chenodeoxycholic acids). These products will then be further modified by gut bacteria to produce secondary bile acids. A decrease in this conversion is positively correlated with liver cirrhosis. Bile acids can modulate the composition of the microbiota in the gut, where they function as signaling molecules and may constitute a mechanism of quorum sensing. In turn, the microbiota strongly affect bile acid metabolism by promoting deconjugation, dehydrogenation and dehydroxylation. It can also inhibit bile acid synthesis in the liver by alleviation of farnesoid X receptor inhibition in the ileum. Bile acids can induce FMO3 expression by an FXR-dependent mechanism.Martin et al. (2007); Bennett et al. (2013); Gérard (2013); Kakiyama et al. (2013); Martínez et al. (2013); Sayin et al. (2013); Joyce et al. (2014)
LipidsCholesterolThe gut microbiota impact on the host systemic lipid metabolism. When administered as probiotics Bifidobacteria and Lactobacillus can enhance dyslipidemia and insulin resistance. Microbiota have an influence on cholesterol metabolism and weight gain in the host via the bacterial BSH mechanism.Martin et al. (2007); Martínez et al. (2009, 2013); Yu et al. (2013); Joyce et al. (2014)
Methylamines and products of choline metabolismMethylamine, dimethylamine, dimethylglycine, trimethylamine (TMA) and trimethylamine N-oxide (TMAO)Cleavage of choline and phosphatidylcholine (PC) by the gut microbiota via the enzyme choline TMA-lyase produces TMA. Oxidation of TMA by hepatic flavin-containing monooxygenase 3 (FMO3) forms TMAO. Microbial metabolism of L-carnitine also produces TMA via a novel Rieske-type protein. Risk for major adverse cardiovascular events coincides with higher levels of TMAO.Wang et al. (2011); Craciun and Balskus (2012); Koeth et al. (2013); Tang et al. (2013); Zhu et al. (2014)
NeurotransmittersSerotonin, melatonin, glutamate, GABA, noradrenaline, dopamine and acetylcholineIt was recently discovered that gut microbiota produce tryptophan decarboxylase, the enzyme responsible for decarboxylasing tryptophan to tryptamine. Tryptamine promotes the release of serotonin by enterochromaffin cells. In a rat model it was shown that Bifidobacteria treatment resulted in increased tryptophan and kynurenic acid levels. Another study in mice showed the potential of Lactobacillus rhamnosus to modulate the GABAergic system. Decreased levels of dopamine were measured in fecal samples from active colitis mice.Desbonnet et al. (2008); Bravo et al. (2011); Rooks et al. (2014); Williams et al. (2014); O'Mahony et al. (2015)
Phytochemicals, particularly polyphenolic compoundsChlorogenic acids, hydrolysable tannins and flavonoidsA significant amount of polyphenols reaches the colon and is believed to contribute to gut health by promoting the growth of some commensals. Polyphenolic bioconversion by microbiota is paramount in the production of a large range of bioactive molecules. The exact roles of these molecules in health and disease are yet to be fully understood. Nonetheless epidemiological studies have tied polyphenols to health benefits such as antioxidative, anticarinogenic, antiadipogenic, antidiabetic and neuroprotective properties. Gut microbiota can also convert dietary polyphenols to benzoate.Tomas-Barberan et al. (2014); Kahle et al. (2006); Aronov et al. (2011); van Duynhoven et al. (2011); Cardona et al. (2013); Marín et al. (2015)
Polyunsaturated fatty acids (PUFA)Omega 3 and 6L. plantarum has genes encoding for the enzyme involved in saturation metabolism of PUFA.Kishino et al. (2013)
Short-chain fatty acids (SCFAs)Most abundant acetate, propionate, butyrate; to a lesser extent—formate, fumarate, malonate, succinate, caproate and valerateThe SCFAs are produced from bacterial fermentation of non-digestible polysaccharides. They play a role in metabolic syndrome prevention and treatment. Evidence point to their potential to promote metabolic control in type 2 diabetes. SCFAs are a major source of energy for colonocytes and also contribute up to 10% of the host's daily caloric requirements. They are further involved in the control of energy utilization and maintenance of metabolic homeostasis via the G Protein coupled Receptor 43 (GPR43) receptor. SCFA products also dampen inflammatory response through this receptor. SCFAs have also been shown to affect cell proliferation and apoptosis (in cancer cells), and in epigenetic machinery such as histone acetylation by butyrate.Bergman (1990); Maslowski et al. (2009); den Besten et al. (2013); Kimura et al. (2013); Natarajan and Pluznick (2014); Puddu et al. (2014)
VitaminsB-group vitamins, vitamin B12; vitamin C, biotin, vitamin KIt is well established that the gut microbiota synthesize a large number of vitamins de novo. This is important since humans lack biosynthetic pathways for vitamins. The deleterious effects of vitamin deficiencies are well known. It has only recently been suggested that vitamin B12 may also contribute to shaping the structure and function of microbial communities in the human gut.Hill (1997); Cooke, Behan and Costello (2006); Arumugam et al. (2011); LeBlanc et al. (2013); Degnan, Taga and Goodman (2014)
Other noteworthy bioactives
Conjugated linoleic acid (CLA), bacteriocinCLA is associated with a diverse array of biological activities, and predominantly associated with activation of peroxisome proliferator activated receptors (PPARs) and the associated switching on and off of genes. Some Bifidobacteria and Lactobacillus species have been shown to produce CLA. Bacteriocins are peptides synthesized by bacteria and have narrow (same species) or broad (across genera) spectrum activity against other bacteria. A large number of archaea and bacteria are believed to produce at least one bacteriocin.Bowdish, Davidson and Hancock (2005); Ross et al. (2010)
Tetrathionate and nitric oxideTetrathionate and nitric oxide are produced in an inflammatory environment and are central to the fitness of several Enterobacteriaceae. Tetrathionate utilization positively correlated with active colitis in a mouse model. Bacterial growth depends on the presence of nitrogen. Synthesis of amino acids by the microbiome depends on the recycling of nitrogen back into gastrointestinal organs.Winter et al. (2010); Bergen (2014); Rooks et al. (2014)
Table 2.

Some examples of small molecule gut metabolites whose secretion has been implicated in various disease states.

MetaboliteIntermediates/productsSynthesisRole in health and diseaseReferences
Amino acidsThe gut microbiota is not itself an important source of amino acids during periods of adequate protein intake. Some commensal members produce biologically active components from amino acids. Amino acid supplementation in a mouse model of ulcerative colitis has been shown to promote overall growth of commensal microbiota. The effect was considered to be mediated via the stimulatory effect on mucin production by amino acid supplementation.Faure et al. (2006); Devaraj, Hemarajata and Versalovic (2013); Bergen (2014)
BenzoatesBenzoic acid, hippurate, 2-hydroxyhippurateGut microbiota in mice with active colitis displayed enrichment for genes involved in benzoate degradation. Hippurate derives from plant food polyphenols and is a conjugate of benzoic acid with glycine. In humans a large portion of hippurate is believed to be derived from precursors absorbed in the small intestines. It is reliably decreased in IBD.Rechner et al. (2002); Aronov et al. (2011); De Preter and Verbeke (2013); Rooks et al. (2014)
Bile acidsBile acids are synthesized from cholesterol in the liver and further metabolized into secondary bile acids by the gut microbiota. The amino acid sides chain of glyco- and tauro-conjugated bile acids are cleaved by bacterial bile salt hydrolase (BSH) enzyme to yield unconjugated bile acids (cholic and chenodeoxycholic acids). These products will then be further modified by gut bacteria to produce secondary bile acids. A decrease in this conversion is positively correlated with liver cirrhosis. Bile acids can modulate the composition of the microbiota in the gut, where they function as signaling molecules and may constitute a mechanism of quorum sensing. In turn, the microbiota strongly affect bile acid metabolism by promoting deconjugation, dehydrogenation and dehydroxylation. It can also inhibit bile acid synthesis in the liver by alleviation of farnesoid X receptor inhibition in the ileum. Bile acids can induce FMO3 expression by an FXR-dependent mechanism.Martin et al. (2007); Bennett et al. (2013); Gérard (2013); Kakiyama et al. (2013); Martínez et al. (2013); Sayin et al. (2013); Joyce et al. (2014)
LipidsCholesterolThe gut microbiota impact on the host systemic lipid metabolism. When administered as probiotics Bifidobacteria and Lactobacillus can enhance dyslipidemia and insulin resistance. Microbiota have an influence on cholesterol metabolism and weight gain in the host via the bacterial BSH mechanism.Martin et al. (2007); Martínez et al. (2009, 2013); Yu et al. (2013); Joyce et al. (2014)
Methylamines and products of choline metabolismMethylamine, dimethylamine, dimethylglycine, trimethylamine (TMA) and trimethylamine N-oxide (TMAO)Cleavage of choline and phosphatidylcholine (PC) by the gut microbiota via the enzyme choline TMA-lyase produces TMA. Oxidation of TMA by hepatic flavin-containing monooxygenase 3 (FMO3) forms TMAO. Microbial metabolism of L-carnitine also produces TMA via a novel Rieske-type protein. Risk for major adverse cardiovascular events coincides with higher levels of TMAO.Wang et al. (2011); Craciun and Balskus (2012); Koeth et al. (2013); Tang et al. (2013); Zhu et al. (2014)
NeurotransmittersSerotonin, melatonin, glutamate, GABA, noradrenaline, dopamine and acetylcholineIt was recently discovered that gut microbiota produce tryptophan decarboxylase, the enzyme responsible for decarboxylasing tryptophan to tryptamine. Tryptamine promotes the release of serotonin by enterochromaffin cells. In a rat model it was shown that Bifidobacteria treatment resulted in increased tryptophan and kynurenic acid levels. Another study in mice showed the potential of Lactobacillus rhamnosus to modulate the GABAergic system. Decreased levels of dopamine were measured in fecal samples from active colitis mice.Desbonnet et al. (2008); Bravo et al. (2011); Rooks et al. (2014); Williams et al. (2014); O'Mahony et al. (2015)
Phytochemicals, particularly polyphenolic compoundsChlorogenic acids, hydrolysable tannins and flavonoidsA significant amount of polyphenols reaches the colon and is believed to contribute to gut health by promoting the growth of some commensals. Polyphenolic bioconversion by microbiota is paramount in the production of a large range of bioactive molecules. The exact roles of these molecules in health and disease are yet to be fully understood. Nonetheless epidemiological studies have tied polyphenols to health benefits such as antioxidative, anticarinogenic, antiadipogenic, antidiabetic and neuroprotective properties. Gut microbiota can also convert dietary polyphenols to benzoate.Tomas-Barberan et al. (2014); Kahle et al. (2006); Aronov et al. (2011); van Duynhoven et al. (2011); Cardona et al. (2013); Marín et al. (2015)
Polyunsaturated fatty acids (PUFA)Omega 3 and 6L. plantarum has genes encoding for the enzyme involved in saturation metabolism of PUFA.Kishino et al. (2013)
Short-chain fatty acids (SCFAs)Most abundant acetate, propionate, butyrate; to a lesser extent—formate, fumarate, malonate, succinate, caproate and valerateThe SCFAs are produced from bacterial fermentation of non-digestible polysaccharides. They play a role in metabolic syndrome prevention and treatment. Evidence point to their potential to promote metabolic control in type 2 diabetes. SCFAs are a major source of energy for colonocytes and also contribute up to 10% of the host's daily caloric requirements. They are further involved in the control of energy utilization and maintenance of metabolic homeostasis via the G Protein coupled Receptor 43 (GPR43) receptor. SCFA products also dampen inflammatory response through this receptor. SCFAs have also been shown to affect cell proliferation and apoptosis (in cancer cells), and in epigenetic machinery such as histone acetylation by butyrate.Bergman (1990); Maslowski et al. (2009); den Besten et al. (2013); Kimura et al. (2013); Natarajan and Pluznick (2014); Puddu et al. (2014)
VitaminsB-group vitamins, vitamin B12; vitamin C, biotin, vitamin KIt is well established that the gut microbiota synthesize a large number of vitamins de novo. This is important since humans lack biosynthetic pathways for vitamins. The deleterious effects of vitamin deficiencies are well known. It has only recently been suggested that vitamin B12 may also contribute to shaping the structure and function of microbial communities in the human gut.Hill (1997); Cooke, Behan and Costello (2006); Arumugam et al. (2011); LeBlanc et al. (2013); Degnan, Taga and Goodman (2014)
Other noteworthy bioactives
Conjugated linoleic acid (CLA), bacteriocinCLA is associated with a diverse array of biological activities, and predominantly associated with activation of peroxisome proliferator activated receptors (PPARs) and the associated switching on and off of genes. Some Bifidobacteria and Lactobacillus species have been shown to produce CLA. Bacteriocins are peptides synthesized by bacteria and have narrow (same species) or broad (across genera) spectrum activity against other bacteria. A large number of archaea and bacteria are believed to produce at least one bacteriocin.Bowdish, Davidson and Hancock (2005); Ross et al. (2010)
Tetrathionate and nitric oxideTetrathionate and nitric oxide are produced in an inflammatory environment and are central to the fitness of several Enterobacteriaceae. Tetrathionate utilization positively correlated with active colitis in a mouse model. Bacterial growth depends on the presence of nitrogen. Synthesis of amino acids by the microbiome depends on the recycling of nitrogen back into gastrointestinal organs.Winter et al. (2010); Bergen (2014); Rooks et al. (2014)
MetaboliteIntermediates/productsSynthesisRole in health and diseaseReferences
Amino acidsThe gut microbiota is not itself an important source of amino acids during periods of adequate protein intake. Some commensal members produce biologically active components from amino acids. Amino acid supplementation in a mouse model of ulcerative colitis has been shown to promote overall growth of commensal microbiota. The effect was considered to be mediated via the stimulatory effect on mucin production by amino acid supplementation.Faure et al. (2006); Devaraj, Hemarajata and Versalovic (2013); Bergen (2014)
BenzoatesBenzoic acid, hippurate, 2-hydroxyhippurateGut microbiota in mice with active colitis displayed enrichment for genes involved in benzoate degradation. Hippurate derives from plant food polyphenols and is a conjugate of benzoic acid with glycine. In humans a large portion of hippurate is believed to be derived from precursors absorbed in the small intestines. It is reliably decreased in IBD.Rechner et al. (2002); Aronov et al. (2011); De Preter and Verbeke (2013); Rooks et al. (2014)
Bile acidsBile acids are synthesized from cholesterol in the liver and further metabolized into secondary bile acids by the gut microbiota. The amino acid sides chain of glyco- and tauro-conjugated bile acids are cleaved by bacterial bile salt hydrolase (BSH) enzyme to yield unconjugated bile acids (cholic and chenodeoxycholic acids). These products will then be further modified by gut bacteria to produce secondary bile acids. A decrease in this conversion is positively correlated with liver cirrhosis. Bile acids can modulate the composition of the microbiota in the gut, where they function as signaling molecules and may constitute a mechanism of quorum sensing. In turn, the microbiota strongly affect bile acid metabolism by promoting deconjugation, dehydrogenation and dehydroxylation. It can also inhibit bile acid synthesis in the liver by alleviation of farnesoid X receptor inhibition in the ileum. Bile acids can induce FMO3 expression by an FXR-dependent mechanism.Martin et al. (2007); Bennett et al. (2013); Gérard (2013); Kakiyama et al. (2013); Martínez et al. (2013); Sayin et al. (2013); Joyce et al. (2014)
LipidsCholesterolThe gut microbiota impact on the host systemic lipid metabolism. When administered as probiotics Bifidobacteria and Lactobacillus can enhance dyslipidemia and insulin resistance. Microbiota have an influence on cholesterol metabolism and weight gain in the host via the bacterial BSH mechanism.Martin et al. (2007); Martínez et al. (2009, 2013); Yu et al. (2013); Joyce et al. (2014)
Methylamines and products of choline metabolismMethylamine, dimethylamine, dimethylglycine, trimethylamine (TMA) and trimethylamine N-oxide (TMAO)Cleavage of choline and phosphatidylcholine (PC) by the gut microbiota via the enzyme choline TMA-lyase produces TMA. Oxidation of TMA by hepatic flavin-containing monooxygenase 3 (FMO3) forms TMAO. Microbial metabolism of L-carnitine also produces TMA via a novel Rieske-type protein. Risk for major adverse cardiovascular events coincides with higher levels of TMAO.Wang et al. (2011); Craciun and Balskus (2012); Koeth et al. (2013); Tang et al. (2013); Zhu et al. (2014)
NeurotransmittersSerotonin, melatonin, glutamate, GABA, noradrenaline, dopamine and acetylcholineIt was recently discovered that gut microbiota produce tryptophan decarboxylase, the enzyme responsible for decarboxylasing tryptophan to tryptamine. Tryptamine promotes the release of serotonin by enterochromaffin cells. In a rat model it was shown that Bifidobacteria treatment resulted in increased tryptophan and kynurenic acid levels. Another study in mice showed the potential of Lactobacillus rhamnosus to modulate the GABAergic system. Decreased levels of dopamine were measured in fecal samples from active colitis mice.Desbonnet et al. (2008); Bravo et al. (2011); Rooks et al. (2014); Williams et al. (2014); O'Mahony et al. (2015)
Phytochemicals, particularly polyphenolic compoundsChlorogenic acids, hydrolysable tannins and flavonoidsA significant amount of polyphenols reaches the colon and is believed to contribute to gut health by promoting the growth of some commensals. Polyphenolic bioconversion by microbiota is paramount in the production of a large range of bioactive molecules. The exact roles of these molecules in health and disease are yet to be fully understood. Nonetheless epidemiological studies have tied polyphenols to health benefits such as antioxidative, anticarinogenic, antiadipogenic, antidiabetic and neuroprotective properties. Gut microbiota can also convert dietary polyphenols to benzoate.Tomas-Barberan et al. (2014); Kahle et al. (2006); Aronov et al. (2011); van Duynhoven et al. (2011); Cardona et al. (2013); Marín et al. (2015)
Polyunsaturated fatty acids (PUFA)Omega 3 and 6L. plantarum has genes encoding for the enzyme involved in saturation metabolism of PUFA.Kishino et al. (2013)
Short-chain fatty acids (SCFAs)Most abundant acetate, propionate, butyrate; to a lesser extent—formate, fumarate, malonate, succinate, caproate and valerateThe SCFAs are produced from bacterial fermentation of non-digestible polysaccharides. They play a role in metabolic syndrome prevention and treatment. Evidence point to their potential to promote metabolic control in type 2 diabetes. SCFAs are a major source of energy for colonocytes and also contribute up to 10% of the host's daily caloric requirements. They are further involved in the control of energy utilization and maintenance of metabolic homeostasis via the G Protein coupled Receptor 43 (GPR43) receptor. SCFA products also dampen inflammatory response through this receptor. SCFAs have also been shown to affect cell proliferation and apoptosis (in cancer cells), and in epigenetic machinery such as histone acetylation by butyrate.Bergman (1990); Maslowski et al. (2009); den Besten et al. (2013); Kimura et al. (2013); Natarajan and Pluznick (2014); Puddu et al. (2014)
VitaminsB-group vitamins, vitamin B12; vitamin C, biotin, vitamin KIt is well established that the gut microbiota synthesize a large number of vitamins de novo. This is important since humans lack biosynthetic pathways for vitamins. The deleterious effects of vitamin deficiencies are well known. It has only recently been suggested that vitamin B12 may also contribute to shaping the structure and function of microbial communities in the human gut.Hill (1997); Cooke, Behan and Costello (2006); Arumugam et al. (2011); LeBlanc et al. (2013); Degnan, Taga and Goodman (2014)
Other noteworthy bioactives
Conjugated linoleic acid (CLA), bacteriocinCLA is associated with a diverse array of biological activities, and predominantly associated with activation of peroxisome proliferator activated receptors (PPARs) and the associated switching on and off of genes. Some Bifidobacteria and Lactobacillus species have been shown to produce CLA. Bacteriocins are peptides synthesized by bacteria and have narrow (same species) or broad (across genera) spectrum activity against other bacteria. A large number of archaea and bacteria are believed to produce at least one bacteriocin.Bowdish, Davidson and Hancock (2005); Ross et al. (2010)
Tetrathionate and nitric oxideTetrathionate and nitric oxide are produced in an inflammatory environment and are central to the fitness of several Enterobacteriaceae. Tetrathionate utilization positively correlated with active colitis in a mouse model. Bacterial growth depends on the presence of nitrogen. Synthesis of amino acids by the microbiome depends on the recycling of nitrogen back into gastrointestinal organs.Winter et al. (2010); Bergen (2014); Rooks et al. (2014)

By contrast, our theme here is that it is additionally the microbes themselves that can pass from the gut (and other ‘external’ surfaces) into the human body, a phenomenon sometimes known as ‘dysbiosis’, albeit this term is more commonly used with another meaning. We here need to discriminate a changed (pathologic) microbiota in the place of origin from the results of a translocation of microbiota to other areas of the body. In the following sections, we use the term dysbiosis to describe changes in a microbiome in its main origin (typically the gut), and we coin the term ‘atopobiosis’ to describe microbes that appear in places other than where they should be.

The origin of detectable but non-proliferating microbes appears to be mainly via ‘atopobiosis’ of the gut microbiome

Dysbiosis, also known as dysbacteriosis, particularly referring to microbial imbalance in the digestive tract, has been widely discussed (e.g. Scher and Abramson 2011; Scanlan et al.2012; Amar et al.2013; Bested, Logan and Selhub 2013; Duytschaever et al.2013; Vaarala 2013). Core to this literature is the idea that factors that lead to significant changes in the gut microbiota composition (dysbiosis) ultimately result in pathology (Larsen et al.2010; Amar et al.2011, 2013; Bested, Logan and Selhub 2013; Burcelin et al.2013; De Angelis et al.2013; Fremont et al.2013; Lanter, Sauer and Davies 2014; Petriz et al.2014; Power et al.2014; Tojo et al.2014). Table 3 gives a list of diseases, largely inflammatory diseases, which have been associated with gut dysbiosis.

Table 3.

Various pathologies that have been associated with dysbiosis of the gut.

ConditionReferences
AsthmaAbrahamsson et al. (2014)
ADKarri, Martinez and Coimbatore (2010); Alam et al. (2014)
AtherosclerosisKoren et al. (2011)
Autism spectrum disordersParracho et al. (2005); Finegold et al. (2010); Adams et al. (2011); Williams et al. (2011, 2012); De Angelis et al. (2013); Kang et al. (2013)
β-Cell autoimmunityde Goffau et al. (2014)
Cardiovascular diseaseAmar et al. (2011)
Crohn's diseaseSeksik et al. (2003)
Chronic fatigue syndromeSheedy et al. (2009); Proal et al. (2013)
Cystic fibrosisScanlan et al. (2012); Bruzzese et al. (2014) ;Sánchez-Calvo et al. (2008); Duytschaever et al. (2011, 2013); Madan et al. (2012)
HIV/AIDSLozupone et al. (2013); McHardy et al. (2013); Vujkovic-Cvijin et al. (2013)
IgE-associated eczemaAbrahamsson et al. (2012)
InflammationCani et al. (2008, 2012); Delzenne and Cani (2011); Delzenne et al. (2011)
Inflammatory bowel diseaseConte et al. (2006); Clemente et al. (2012); Manichanh et al. (2012); Morgan et al. (2012); Nagalingam and Lynch (2012); Bakhtiar et al. (2013)
Iron deficiencyBalamurugan et al. (2010); Zimmermann et al. (2010); Dostal et al. (2012, 2014)
Liver diseaseSchnabl and Brenner (2014)
Multiple sclerosisBerer et al. (2011)
ObesityDelzenne and Cani (2011); Geurts et al. (2014)
Rheumatoid arthritisDetert et al. (2010); Berer et al. (2011); Scher and Abramson (2011); Bingham and Moni (2013); Brusca, Abramson and Scher (2014); Catrina, Deane and Scher (2014); Cénit et al. (2014); Demoruelle, Deane and Holers (2014); Taneja (2014)
Parkinson's DiseaseScheperjans et al. (2015); Vizcarra et al. (2015)
SarcoidosisAlmenoff et al. (1996)
Systemic lupus erythematosusHevia et al. (2014); Zhang et al. (2014a)
Symptomatic atherosclerosis/strokeKarlsson et al. (2012)
Type 1 diabetesBrown et al. (2012); Owen and Mohamadzadeh (2013); Petersen and Round (2014)
Type 2 diabetesLarsen et al. (2010); Brown et al. (2012); Qin et al. (2012); Karlsson et al. (2013); Everard et al. (2014)
ConditionReferences
AsthmaAbrahamsson et al. (2014)
ADKarri, Martinez and Coimbatore (2010); Alam et al. (2014)
AtherosclerosisKoren et al. (2011)
Autism spectrum disordersParracho et al. (2005); Finegold et al. (2010); Adams et al. (2011); Williams et al. (2011, 2012); De Angelis et al. (2013); Kang et al. (2013)
β-Cell autoimmunityde Goffau et al. (2014)
Cardiovascular diseaseAmar et al. (2011)
Crohn's diseaseSeksik et al. (2003)
Chronic fatigue syndromeSheedy et al. (2009); Proal et al. (2013)
Cystic fibrosisScanlan et al. (2012); Bruzzese et al. (2014) ;Sánchez-Calvo et al. (2008); Duytschaever et al. (2011, 2013); Madan et al. (2012)
HIV/AIDSLozupone et al. (2013); McHardy et al. (2013); Vujkovic-Cvijin et al. (2013)
IgE-associated eczemaAbrahamsson et al. (2012)
InflammationCani et al. (2008, 2012); Delzenne and Cani (2011); Delzenne et al. (2011)
Inflammatory bowel diseaseConte et al. (2006); Clemente et al. (2012); Manichanh et al. (2012); Morgan et al. (2012); Nagalingam and Lynch (2012); Bakhtiar et al. (2013)
Iron deficiencyBalamurugan et al. (2010); Zimmermann et al. (2010); Dostal et al. (2012, 2014)
Liver diseaseSchnabl and Brenner (2014)
Multiple sclerosisBerer et al. (2011)
ObesityDelzenne and Cani (2011); Geurts et al. (2014)
Rheumatoid arthritisDetert et al. (2010); Berer et al. (2011); Scher and Abramson (2011); Bingham and Moni (2013); Brusca, Abramson and Scher (2014); Catrina, Deane and Scher (2014); Cénit et al. (2014); Demoruelle, Deane and Holers (2014); Taneja (2014)
Parkinson's DiseaseScheperjans et al. (2015); Vizcarra et al. (2015)
SarcoidosisAlmenoff et al. (1996)
Systemic lupus erythematosusHevia et al. (2014); Zhang et al. (2014a)
Symptomatic atherosclerosis/strokeKarlsson et al. (2012)
Type 1 diabetesBrown et al. (2012); Owen and Mohamadzadeh (2013); Petersen and Round (2014)
Type 2 diabetesLarsen et al. (2010); Brown et al. (2012); Qin et al. (2012); Karlsson et al. (2013); Everard et al. (2014)
Table 3.

Various pathologies that have been associated with dysbiosis of the gut.

ConditionReferences
AsthmaAbrahamsson et al. (2014)
ADKarri, Martinez and Coimbatore (2010); Alam et al. (2014)
AtherosclerosisKoren et al. (2011)
Autism spectrum disordersParracho et al. (2005); Finegold et al. (2010); Adams et al. (2011); Williams et al. (2011, 2012); De Angelis et al. (2013); Kang et al. (2013)
β-Cell autoimmunityde Goffau et al. (2014)
Cardiovascular diseaseAmar et al. (2011)
Crohn's diseaseSeksik et al. (2003)
Chronic fatigue syndromeSheedy et al. (2009); Proal et al. (2013)
Cystic fibrosisScanlan et al. (2012); Bruzzese et al. (2014) ;Sánchez-Calvo et al. (2008); Duytschaever et al. (2011, 2013); Madan et al. (2012)
HIV/AIDSLozupone et al. (2013); McHardy et al. (2013); Vujkovic-Cvijin et al. (2013)
IgE-associated eczemaAbrahamsson et al. (2012)
InflammationCani et al. (2008, 2012); Delzenne and Cani (2011); Delzenne et al. (2011)
Inflammatory bowel diseaseConte et al. (2006); Clemente et al. (2012); Manichanh et al. (2012); Morgan et al. (2012); Nagalingam and Lynch (2012); Bakhtiar et al. (2013)
Iron deficiencyBalamurugan et al. (2010); Zimmermann et al. (2010); Dostal et al. (2012, 2014)
Liver diseaseSchnabl and Brenner (2014)
Multiple sclerosisBerer et al. (2011)
ObesityDelzenne and Cani (2011); Geurts et al. (2014)
Rheumatoid arthritisDetert et al. (2010); Berer et al. (2011); Scher and Abramson (2011); Bingham and Moni (2013); Brusca, Abramson and Scher (2014); Catrina, Deane and Scher (2014); Cénit et al. (2014); Demoruelle, Deane and Holers (2014); Taneja (2014)
Parkinson's DiseaseScheperjans et al. (2015); Vizcarra et al. (2015)
SarcoidosisAlmenoff et al. (1996)
Systemic lupus erythematosusHevia et al. (2014); Zhang et al. (2014a)
Symptomatic atherosclerosis/strokeKarlsson et al. (2012)
Type 1 diabetesBrown et al. (2012); Owen and Mohamadzadeh (2013); Petersen and Round (2014)
Type 2 diabetesLarsen et al. (2010); Brown et al. (2012); Qin et al. (2012); Karlsson et al. (2013); Everard et al. (2014)
ConditionReferences
AsthmaAbrahamsson et al. (2014)
ADKarri, Martinez and Coimbatore (2010); Alam et al. (2014)
AtherosclerosisKoren et al. (2011)
Autism spectrum disordersParracho et al. (2005); Finegold et al. (2010); Adams et al. (2011); Williams et al. (2011, 2012); De Angelis et al. (2013); Kang et al. (2013)
β-Cell autoimmunityde Goffau et al. (2014)
Cardiovascular diseaseAmar et al. (2011)
Crohn's diseaseSeksik et al. (2003)
Chronic fatigue syndromeSheedy et al. (2009); Proal et al. (2013)
Cystic fibrosisScanlan et al. (2012); Bruzzese et al. (2014) ;Sánchez-Calvo et al. (2008); Duytschaever et al. (2011, 2013); Madan et al. (2012)
HIV/AIDSLozupone et al. (2013); McHardy et al. (2013); Vujkovic-Cvijin et al. (2013)
IgE-associated eczemaAbrahamsson et al. (2012)
InflammationCani et al. (2008, 2012); Delzenne and Cani (2011); Delzenne et al. (2011)
Inflammatory bowel diseaseConte et al. (2006); Clemente et al. (2012); Manichanh et al. (2012); Morgan et al. (2012); Nagalingam and Lynch (2012); Bakhtiar et al. (2013)
Iron deficiencyBalamurugan et al. (2010); Zimmermann et al. (2010); Dostal et al. (2012, 2014)
Liver diseaseSchnabl and Brenner (2014)
Multiple sclerosisBerer et al. (2011)
ObesityDelzenne and Cani (2011); Geurts et al. (2014)
Rheumatoid arthritisDetert et al. (2010); Berer et al. (2011); Scher and Abramson (2011); Bingham and Moni (2013); Brusca, Abramson and Scher (2014); Catrina, Deane and Scher (2014); Cénit et al. (2014); Demoruelle, Deane and Holers (2014); Taneja (2014)
Parkinson's DiseaseScheperjans et al. (2015); Vizcarra et al. (2015)
SarcoidosisAlmenoff et al. (1996)
Systemic lupus erythematosusHevia et al. (2014); Zhang et al. (2014a)
Symptomatic atherosclerosis/strokeKarlsson et al. (2012)
Type 1 diabetesBrown et al. (2012); Owen and Mohamadzadeh (2013); Petersen and Round (2014)
Type 2 diabetesLarsen et al. (2010); Brown et al. (2012); Qin et al. (2012); Karlsson et al. (2013); Everard et al. (2014)

In addition, we argue here that as well as gut dysbiosis, a derangement of the gut microbiome, what we are seeing here, often called ‘translocation’ in the context of surgery (Swank and Deitch 1996; MacFie 2004) and various diseases (Berg 1995) (see Table 4 that lists diseases and conditions where bacterial translocation is specifically implicated), is what might better be called atopobiosis (Greek ατoπoς or atopos, in the wrong place), i.e. an appearance of members of the gut (or other) microbiome in the wrong place. Bacterial translocation is therefore discussed in the context of the movement of gut origin microbes [that changed from normal (dysbiosis)] that moved across the ‘intact’ gastrointestinal tract into normally sterile tissues, including blood, where the organisms may then directly cause infection or inflammation leading to tissue injury, organ failure, etc. (Steinberg 2003; Wiest and Rath 2003; Balzan et al.2007). We stress that they may be found in both infectious and non-infectious diseases as well as being translocated during surgery, and that atopobiosis of bacteria originating in the oral cavity, e.g. in periodontal disease, may also be significant in rheumatoid arthritis, for instance (see below). Fig. 3 provides a schematic representation of dysbiosis, bacterial translocation and atopobiosis.

Schematic representation of dysbiosis, bacterial translocation and atopobiosis. (A) When intestinal microbiota are associated with dysbiosis, (B) the gut barrier (1 and 2) becomes compromised; this leads to (C), a route of entry via the gut epithelia causing (D) bacterial translocation. Bacterial translocation is also associated with a compromised systemic immune system barrier (3). Therefore, intestinal microbiota dysbiosis (A) followed by bacterial translocation (D) results in (E) atopobiosis. (F) The results of bacterial translocation are seen in various conditions (see Table 4).
Figure 3.

Schematic representation of dysbiosis, bacterial translocation and atopobiosis. (A) When intestinal microbiota are associated with dysbiosis, (B) the gut barrier (1 and 2) becomes compromised; this leads to (C), a route of entry via the gut epithelia causing (D) bacterial translocation. Bacterial translocation is also associated with a compromised systemic immune system barrier (3). Therefore, intestinal microbiota dysbiosis (A) followed by bacterial translocation (D) results in (E) atopobiosis. (F) The results of bacterial translocation are seen in various conditions (see Table 4).

Table 4.

Diseases and conditions where bacterial translocation (of gut or oral origin) and consequent chronic infection are specifically implicated

Diseases and conditions where translocation of bacteria are presentReferences
Communicable diseases
Fibrosis stage in HIV/HCV coinfectionBalagopal et al. (2008); Montes-de-Oca et al. (2011); Page, Nelson and Kelleher (2011); Lin, Weinberg and Chung (2013); Sacchi et al. (2015)
Hepatitis C virus (HCV) infectionFrench et al. (2013); Munteanu et al. (2014)
HIV/AIDS infectionSandler and Douek (2012); Klatt, Funderburg and Brenchley (2013); Vázquez-Castellanos et al. (2014)
Pneumonia in immunocompromised patientsSawa (2014)
Diseases usually seen as non-communicable
Abdominal compartment syndromeMifkovic et al. (2013)
Alcoholic liver diseaseChen and Schnabl (2014); Malaguarnera et al. (2014)
Allergic disease: bacterial translocation during pregnancyAbrahamsson Wu and Jenmalm (2015)
AtherosclerosisEpstein, Zhou and Zhu (1999); Kozarov et al. (2006); Erridge (2008); Renko et al. (2008); Epstein et al. (2009); Nagata, de Toledo and Oho (2011); Rosenfeld and Campbell (2011); Hopkins (2013); Dinakaran et al. (2014); Rogler and Rosano (2014); Trøseid et al. (2014)
Burn woundsMacintire and Bellhorn (2002); Sharma (2007); Aboelatta et al. (2013)
CirrhosisWiest and Garcia-Tsao (2005); Jun et al. (2010); Giannelli et al. (2014); Wiest, Lawson and Geuking (2014)
Chronic kidney diseaseAnders, Andersen and Stecher (2013); Sabatino et al. (2014)
Metabolic syndromeFesti et al. (2014)
Non-alcoholic fatty liver diseaseBieghs and Trautwein (2014)
ObesityVajro, Paolella and Fasano (2013); Sanz and Moya-Pérez (2014)
PancreatitisMifkovic et al. (2009); Guo et al. (2014); Oláh and Romics (2014)
Rheumatoid arthritisOgrendik (2009b, 2013b); Ebringer and Rashid (2014); Koziel, Mydel and Potempa (2014)
SchizophreniaSeverance et al. (2013); Severance, Yolken and Eaton (2014)
Sepsis and Septic shock*Tsujimoto, Ono and Mochizuki (2009); Wallet et al. (2011); Deitch (2012); Leli et al. (2014)
StrokeSyrjänen et al. (1988); Emsley and Tyrrell (2002); Emsley et al. (2003); Emsley and Hopkins (2008); McColl, Allan and Rothwell (2009); Emsley and Chamorro (2010); Grau, Urbanek and Palm (2010); Wang et al. (2012a); Chien et al. (2013); Dalager-Pedersen et al. (2014); Fugate et al. (2014)
Surgical procedures
Bariatric surgeryFesti et al. (2014)
Cardiac surgeryAllen (2014)
Multiple organ failure (MOF)Swank and Deitch (1996)
Sepsis due to surgeryMacFie (2004); Puleo et al. (2011)
Diseases and conditions where translocation of bacteria are presentReferences
Communicable diseases
Fibrosis stage in HIV/HCV coinfectionBalagopal et al. (2008); Montes-de-Oca et al. (2011); Page, Nelson and Kelleher (2011); Lin, Weinberg and Chung (2013); Sacchi et al. (2015)
Hepatitis C virus (HCV) infectionFrench et al. (2013); Munteanu et al. (2014)
HIV/AIDS infectionSandler and Douek (2012); Klatt, Funderburg and Brenchley (2013); Vázquez-Castellanos et al. (2014)
Pneumonia in immunocompromised patientsSawa (2014)
Diseases usually seen as non-communicable
Abdominal compartment syndromeMifkovic et al. (2013)
Alcoholic liver diseaseChen and Schnabl (2014); Malaguarnera et al. (2014)
Allergic disease: bacterial translocation during pregnancyAbrahamsson Wu and Jenmalm (2015)
AtherosclerosisEpstein, Zhou and Zhu (1999); Kozarov et al. (2006); Erridge (2008); Renko et al. (2008); Epstein et al. (2009); Nagata, de Toledo and Oho (2011); Rosenfeld and Campbell (2011); Hopkins (2013); Dinakaran et al. (2014); Rogler and Rosano (2014); Trøseid et al. (2014)
Burn woundsMacintire and Bellhorn (2002); Sharma (2007); Aboelatta et al. (2013)
CirrhosisWiest and Garcia-Tsao (2005); Jun et al. (2010); Giannelli et al. (2014); Wiest, Lawson and Geuking (2014)
Chronic kidney diseaseAnders, Andersen and Stecher (2013); Sabatino et al. (2014)
Metabolic syndromeFesti et al. (2014)
Non-alcoholic fatty liver diseaseBieghs and Trautwein (2014)
ObesityVajro, Paolella and Fasano (2013); Sanz and Moya-Pérez (2014)
PancreatitisMifkovic et al. (2009); Guo et al. (2014); Oláh and Romics (2014)
Rheumatoid arthritisOgrendik (2009b, 2013b); Ebringer and Rashid (2014); Koziel, Mydel and Potempa (2014)
SchizophreniaSeverance et al. (2013); Severance, Yolken and Eaton (2014)
Sepsis and Septic shock*Tsujimoto, Ono and Mochizuki (2009); Wallet et al. (2011); Deitch (2012); Leli et al. (2014)
StrokeSyrjänen et al. (1988); Emsley and Tyrrell (2002); Emsley et al. (2003); Emsley and Hopkins (2008); McColl, Allan and Rothwell (2009); Emsley and Chamorro (2010); Grau, Urbanek and Palm (2010); Wang et al. (2012a); Chien et al. (2013); Dalager-Pedersen et al. (2014); Fugate et al. (2014)
Surgical procedures
Bariatric surgeryFesti et al. (2014)
Cardiac surgeryAllen (2014)
Multiple organ failure (MOF)Swank and Deitch (1996)
Sepsis due to surgeryMacFie (2004); Puleo et al. (2011)

*‘Sepsis’ is widely used to imply living microbes, but as is now well known it can also occur in the absence of any culturable microbes, including those incapable of proliferation due to antibiotic activity. Sepsis may commonly result simply from the effects of molecules such as LPS on the generation of inflammatory cytokines (Kotsaki and Giamarellos-Bourboulis 2012; Balakrishnan et al.2013).

Table 4.

Diseases and conditions where bacterial translocation (of gut or oral origin) and consequent chronic infection are specifically implicated

Diseases and conditions where translocation of bacteria are presentReferences
Communicable diseases
Fibrosis stage in HIV/HCV coinfectionBalagopal et al. (2008); Montes-de-Oca et al. (2011); Page, Nelson and Kelleher (2011); Lin, Weinberg and Chung (2013); Sacchi et al. (2015)
Hepatitis C virus (HCV) infectionFrench et al. (2013); Munteanu et al. (2014)
HIV/AIDS infectionSandler and Douek (2012); Klatt, Funderburg and Brenchley (2013); Vázquez-Castellanos et al. (2014)
Pneumonia in immunocompromised patientsSawa (2014)
Diseases usually seen as non-communicable
Abdominal compartment syndromeMifkovic et al. (2013)
Alcoholic liver diseaseChen and Schnabl (2014); Malaguarnera et al. (2014)
Allergic disease: bacterial translocation during pregnancyAbrahamsson Wu and Jenmalm (2015)
AtherosclerosisEpstein, Zhou and Zhu (1999); Kozarov et al. (2006); Erridge (2008); Renko et al. (2008); Epstein et al. (2009); Nagata, de Toledo and Oho (2011); Rosenfeld and Campbell (2011); Hopkins (2013); Dinakaran et al. (2014); Rogler and Rosano (2014); Trøseid et al. (2014)
Burn woundsMacintire and Bellhorn (2002); Sharma (2007); Aboelatta et al. (2013)
CirrhosisWiest and Garcia-Tsao (2005); Jun et al. (2010); Giannelli et al. (2014); Wiest, Lawson and Geuking (2014)
Chronic kidney diseaseAnders, Andersen and Stecher (2013); Sabatino et al. (2014)
Metabolic syndromeFesti et al. (2014)
Non-alcoholic fatty liver diseaseBieghs and Trautwein (2014)
ObesityVajro, Paolella and Fasano (2013); Sanz and Moya-Pérez (2014)
PancreatitisMifkovic et al. (2009); Guo et al. (2014); Oláh and Romics (2014)
Rheumatoid arthritisOgrendik (2009b, 2013b); Ebringer and Rashid (2014); Koziel, Mydel and Potempa (2014)
SchizophreniaSeverance et al. (2013); Severance, Yolken and Eaton (2014)
Sepsis and Septic shock*Tsujimoto, Ono and Mochizuki (2009); Wallet et al. (2011); Deitch (2012); Leli et al. (2014)
StrokeSyrjänen et al. (1988); Emsley and Tyrrell (2002); Emsley et al. (2003); Emsley and Hopkins (2008); McColl, Allan and Rothwell (2009); Emsley and Chamorro (2010); Grau, Urbanek and Palm (2010); Wang et al. (2012a); Chien et al. (2013); Dalager-Pedersen et al. (2014); Fugate et al. (2014)
Surgical procedures
Bariatric surgeryFesti et al. (2014)
Cardiac surgeryAllen (2014)
Multiple organ failure (MOF)Swank and Deitch (1996)
Sepsis due to surgeryMacFie (2004); Puleo et al. (2011)
Diseases and conditions where translocation of bacteria are presentReferences
Communicable diseases
Fibrosis stage in HIV/HCV coinfectionBalagopal et al. (2008); Montes-de-Oca et al. (2011); Page, Nelson and Kelleher (2011); Lin, Weinberg and Chung (2013); Sacchi et al. (2015)
Hepatitis C virus (HCV) infectionFrench et al. (2013); Munteanu et al. (2014)
HIV/AIDS infectionSandler and Douek (2012); Klatt, Funderburg and Brenchley (2013); Vázquez-Castellanos et al. (2014)
Pneumonia in immunocompromised patientsSawa (2014)
Diseases usually seen as non-communicable
Abdominal compartment syndromeMifkovic et al. (2013)
Alcoholic liver diseaseChen and Schnabl (2014); Malaguarnera et al. (2014)
Allergic disease: bacterial translocation during pregnancyAbrahamsson Wu and Jenmalm (2015)
AtherosclerosisEpstein, Zhou and Zhu (1999); Kozarov et al. (2006); Erridge (2008); Renko et al. (2008); Epstein et al. (2009); Nagata, de Toledo and Oho (2011); Rosenfeld and Campbell (2011); Hopkins (2013); Dinakaran et al. (2014); Rogler and Rosano (2014); Trøseid et al. (2014)
Burn woundsMacintire and Bellhorn (2002); Sharma (2007); Aboelatta et al. (2013)
CirrhosisWiest and Garcia-Tsao (2005); Jun et al. (2010); Giannelli et al. (2014); Wiest, Lawson and Geuking (2014)
Chronic kidney diseaseAnders, Andersen and Stecher (2013); Sabatino et al. (2014)
Metabolic syndromeFesti et al. (2014)
Non-alcoholic fatty liver diseaseBieghs and Trautwein (2014)
ObesityVajro, Paolella and Fasano (2013); Sanz and Moya-Pérez (2014)
PancreatitisMifkovic et al. (2009); Guo et al. (2014); Oláh and Romics (2014)
Rheumatoid arthritisOgrendik (2009b, 2013b); Ebringer and Rashid (2014); Koziel, Mydel and Potempa (2014)
SchizophreniaSeverance et al. (2013); Severance, Yolken and Eaton (2014)
Sepsis and Septic shock*Tsujimoto, Ono and Mochizuki (2009); Wallet et al. (2011); Deitch (2012); Leli et al. (2014)
StrokeSyrjänen et al. (1988); Emsley and Tyrrell (2002); Emsley et al. (2003); Emsley and Hopkins (2008); McColl, Allan and Rothwell (2009); Emsley and Chamorro (2010); Grau, Urbanek and Palm (2010); Wang et al. (2012a); Chien et al. (2013); Dalager-Pedersen et al. (2014); Fugate et al. (2014)
Surgical procedures
Bariatric surgeryFesti et al. (2014)
Cardiac surgeryAllen (2014)
Multiple organ failure (MOF)Swank and Deitch (1996)
Sepsis due to surgeryMacFie (2004); Puleo et al. (2011)

*‘Sepsis’ is widely used to imply living microbes, but as is now well known it can also occur in the absence of any culturable microbes, including those incapable of proliferation due to antibiotic activity. Sepsis may commonly result simply from the effects of molecules such as LPS on the generation of inflammatory cytokines (Kotsaki and Giamarellos-Bourboulis 2012; Balakrishnan et al.2013).

How do gut bacteria escape into blood?

If the gut microbiome is seen as the main source of the blood microbiome, it is necessary to establish which kinds of conditions might permit this in the absence of real physical damage (as may, for instance, be caused by surgery) leading to microbial translocation. Wiest, Lawson and Geuking (2014) mention three possible points of entrance for bacteria into the surrounding (sterile) tissue:

  • by dendritic cells via processes between epithelial cells, not affecting tight junction function,

  • via injured/inflamed epithelium with dysfunctional epithelial barrier,

  • and via M cells overlying Peyer's patches as specialized cells providing access of microbial products to antigen-presenting cells.

We discuss bacterial translocation in this context in the following sections.

The role of M cells and Peyer's patches in gut microbial translocation and atopobiosis

While the gut epithelium represents the largest mucosal tissue, the mechanisms underlying the interaction between the microbiome and the epithelial cells remain poorly understood (Mathias et al.2014). Although this is a vast and complex field that warrants a review of its own, we briefly argue that gut dysbiosis results in an atypical interaction of both the microbiota, as well as their secretory products, with the gut epithelial layer. This results in an altered barrier function, which may also lead to changed mucosal immunity and ultimately to atopobiosis. The gut epithelium is necessarily normally quite impermeable to microbes, but there is increasing evidence that direct chemical communication between the microbiota and the epithelial cells regulates mucosal integrity (Venkatesh et al.2014). A possible point of entry is by direct cellular uptake, and there is one type of cell that can take up microbes, and these are the M cells overlaying the Peyer's patches (Kernéis et al.1997; Jepson and Clark 1998; Clark and Jepson 2003; Corr, Gahan and Hill 2008; Lelouard et al.2010; Fukuda, Hase and Ohno 2011). Peyer's patches are seen as the ‘immune sensors’ of the gut epithelium. Considerable evidence exists that they provide a primary route for the limited translocation of microbes between the gut epithelium and the blood system (Jung, Hugot and Barreau 2010). These interactions with the cells of the gut may suggest that changes in the intestinal microbiota also influence mucosal immunity (Sato, Kiyono and Fujihashi et al.2014). This is indeed the case, and gut dysbiosis has been shown to play a significant role in the development of autoimmune diseases, in particular inflammatory bowel diseases (Clemente et al.2012; Morgan et al.2012; Hold et al.2014; Kostic, Xavier and Gevers 2014; Owyang and Wu 2014; Ma et al.2015). It was also suggested that a changed gut microbiota represents the initial site of autoimmunity generation, and might be a critical epigenetic factor in autoimmune diseases such as rheumatoid arthritis (Scher and Abramson 2011; Luckey et al.2013; Brusca, Abramson and Scher 2014; Catrina, Deane and Scher 2014; Cénit et al.2014; Taneja 2014). There is also evidence that regulatory T cells in the gut are influenced by microbial factors, and that a changed microbiota (dysbiosis) may influence the induction and suppressor functions of these cells, in turn leading to a changed gut mucosal immunity (Kinoshita and Takeda 2014).

We have earlier reviewed the literature that suggests that dysbiosis can cause gut epithelial barrier dysfunction, and thereby provide a point of entry into the body, including the blood, resulting in atopobiosis. This is supported by recent research that has suggested that blood microbiota might be implicated in various (cardiovascular and other) diseases. Sequence-based techniques provided evidence for the presence of such a blood microbiome. The question now arises as to whether such a microbiome's presence can be directly measured by e.g. ultrastructural (microscopic) methods, since a consequence of any translocation of microbes between the gut microbiome and blood is that they should then be observable in blood. The next sections will provide visual evidence of the presence of such a microbiota in Alzheimer's disease (AD) and PD. As shown in Table 3, these conditions are known to be associated with the presence of dysbiosis.

Direct measurement by ultrastructural (microscopic) methods

Direct measurement by ultrastructural (microscopic) methods of analysis shows that microbes are in fact common constituents of blood in inflammatory diseases [previously seen in PD—Fig. 8 in (Pretorius et al.2014a and in AD—Fig. 2 in (Lipinski and Pretorius 2013). We show and annotate selected micrographs from these papers in Fig. 4]. An important concern that needs to be addressed, as is also the case with sequence-based methods, is whether the presence of microbiota in whole blood is indeed not the result of introduced external contamination. There is in fact considerable evidence in the literature that bacteria as well as other microorganisms can reside inside RBCs (e.g. Minasyan 2014), and thus able to cross the RBC membrane somehow (see Table 5). Transmission electron microscopy (TEM) analysis showing bacteria inside cells would also tend to imply that the bacteria were not externally introduced artefactually during the preparation of the samples.

Micrographs taken from previously published manuscripts. (A–C) Bacterial presence in PD, originally shown in Fig. 8A, C and G in Pretorius et al. (2014a). (D) Bacterial presence in AD, originally shown in Fig. 2 in Lipinski and Pretorius (2013).
Figure 4.

Micrographs taken from previously published manuscripts. (AC) Bacterial presence in PD, originally shown in Fig. 8A, C and G in Pretorius et al. (2014a). (D) Bacterial presence in AD, originally shown in Fig. 2 in Lipinski and Pretorius (2013).

Table 5.

Some microorganisms that are known to invade red blood cells.

PathogenType of microorganismMechanism of invasionReferences
Anaplasma marginaleA tick-borne pathogen that causes the disease anaplasmosis in cattle.Via major surface protein 1a (MSP1a)Kocan et al. (2004)
Bartonella bacilliformisB.quintanaBartonella species are fastidious Gram-negative bacteria, which belong to the alpha group of the domain Proteobacteria.The Trw T4SS mediates attachment of Bartonella to red blood cells in Bartonella lineage 4. Bartonella is collected in pits and trenches that form as a result of deformation factor. Invaginations supposedly pinch off to carry the content in a vacuole structure to the cytoplasm of the red blood cell where the organism persists.Iwaki-Egawa and Ihler (1997); Coleman and Minnick (2001); Rolain et al. (2003); Eicher and Dehio (2012)
Brucella melitensisFacultative intracellular Gram-negative coccobacilli.Invasion shown in mouse erythrocytes. Mechanism to be identified.Vitry et al. (2014)
Francisella tularensisHighly infectious bacterium, which can cause severe disease tularemia with an infection of fewer than 10 bacteriaVia serum complement-dependent and independent mechanisms.Conlan (2011); Horzempa et al. (2011)
Mycoplasma suisA member or the hemotrophic mycoplasma group that parasitize erythrocytes in pigs.Invasion occurs in a similar manner to that of P. falciparum and B. bacilliformis. Attachment via MSG1 (GAPDH) protein.Groebel et al. (2009); Zhang et al. (2014c)
M. bovisSmall cell wall-less bacterium that contributes to a number of chronic inflammatory diseases in dairy and feedlot cattle.Undetermined.van der Merwe, Prysliak and Perez-Casal (2010)
M. gallisepticumMycoplasmas are small cell wall-less prokaryotes.Not known.Vogl et al. (2008)
Plasmodium falciparumThe main malaria parasite, part of whose life cycle involves inhabiting RBCs.Recognition of surface receptors precedes a reorientation where the apical end is adjusted to the erythrocyte. A tight junction that involves high-affinity ligand receptor interactions is formed. The tight junction moves from the apical to posterior pole and is powered by the actin-myosin motor of the parasite. The adhesive proteins at the junction are proteolytically removed when the posterior pole is reached, most likely by a rhomboid resident protease in a process that facilitates membrane resealing. The invasion process produces a parasitophorous vacuole containing the merozoite.Cowman and Crabb (2006)
Streptococcus pneumoniaeGram-positive bacterium which causes infection-related diseases.LPXTG motif-containing pneumococcal proteins, erythrocyte lipid rafts and erythrocyte actin remodeling are involved in the invasion mechanism.Yamaguchi et al. (2013)
Theileria sporozitesIntracellular protozoan transmitted by ixodid ticks. Infect wild and domesticated ruminants. Phylogenetically most closely related to Babesia.Occurs in a similar manner to sporozoite entry.Shaw (2003); Bishop et al. (2004)
PathogenType of microorganismMechanism of invasionReferences
Anaplasma marginaleA tick-borne pathogen that causes the disease anaplasmosis in cattle.Via major surface protein 1a (MSP1a)Kocan et al. (2004)
Bartonella bacilliformisB.quintanaBartonella species are fastidious Gram-negative bacteria, which belong to the alpha group of the domain Proteobacteria.The Trw T4SS mediates attachment of Bartonella to red blood cells in Bartonella lineage 4. Bartonella is collected in pits and trenches that form as a result of deformation factor. Invaginations supposedly pinch off to carry the content in a vacuole structure to the cytoplasm of the red blood cell where the organism persists.Iwaki-Egawa and Ihler (1997); Coleman and Minnick (2001); Rolain et al. (2003); Eicher and Dehio (2012)
Brucella melitensisFacultative intracellular Gram-negative coccobacilli.Invasion shown in mouse erythrocytes. Mechanism to be identified.Vitry et al. (2014)
Francisella tularensisHighly infectious bacterium, which can cause severe disease tularemia with an infection of fewer than 10 bacteriaVia serum complement-dependent and independent mechanisms.Conlan (2011); Horzempa et al. (2011)
Mycoplasma suisA member or the hemotrophic mycoplasma group that parasitize erythrocytes in pigs.Invasion occurs in a similar manner to that of P. falciparum and B. bacilliformis. Attachment via MSG1 (GAPDH) protein.Groebel et al. (2009); Zhang et al. (2014c)
M. bovisSmall cell wall-less bacterium that contributes to a number of chronic inflammatory diseases in dairy and feedlot cattle.Undetermined.van der Merwe, Prysliak and Perez-Casal (2010)
M. gallisepticumMycoplasmas are small cell wall-less prokaryotes.Not known.Vogl et al. (2008)
Plasmodium falciparumThe main malaria parasite, part of whose life cycle involves inhabiting RBCs.Recognition of surface receptors precedes a reorientation where the apical end is adjusted to the erythrocyte. A tight junction that involves high-affinity ligand receptor interactions is formed. The tight junction moves from the apical to posterior pole and is powered by the actin-myosin motor of the parasite. The adhesive proteins at the junction are proteolytically removed when the posterior pole is reached, most likely by a rhomboid resident protease in a process that facilitates membrane resealing. The invasion process produces a parasitophorous vacuole containing the merozoite.Cowman and Crabb (2006)
Streptococcus pneumoniaeGram-positive bacterium which causes infection-related diseases.LPXTG motif-containing pneumococcal proteins, erythrocyte lipid rafts and erythrocyte actin remodeling are involved in the invasion mechanism.Yamaguchi et al. (2013)
Theileria sporozitesIntracellular protozoan transmitted by ixodid ticks. Infect wild and domesticated ruminants. Phylogenetically most closely related to Babesia.Occurs in a similar manner to sporozoite entry.Shaw (2003); Bishop et al. (2004)
Table 5.

Some microorganisms that are known to invade red blood cells.

PathogenType of microorganismMechanism of invasionReferences
Anaplasma marginaleA tick-borne pathogen that causes the disease anaplasmosis in cattle.Via major surface protein 1a (MSP1a)Kocan et al. (2004)
Bartonella bacilliformisB.quintanaBartonella species are fastidious Gram-negative bacteria, which belong to the alpha group of the domain Proteobacteria.The Trw T4SS mediates attachment of Bartonella to red blood cells in Bartonella lineage 4. Bartonella is collected in pits and trenches that form as a result of deformation factor. Invaginations supposedly pinch off to carry the content in a vacuole structure to the cytoplasm of the red blood cell where the organism persists.Iwaki-Egawa and Ihler (1997); Coleman and Minnick (2001); Rolain et al. (2003); Eicher and Dehio (2012)
Brucella melitensisFacultative intracellular Gram-negative coccobacilli.Invasion shown in mouse erythrocytes. Mechanism to be identified.Vitry et al. (2014)
Francisella tularensisHighly infectious bacterium, which can cause severe disease tularemia with an infection of fewer than 10 bacteriaVia serum complement-dependent and independent mechanisms.Conlan (2011); Horzempa et al. (2011)
Mycoplasma suisA member or the hemotrophic mycoplasma group that parasitize erythrocytes in pigs.Invasion occurs in a similar manner to that of P. falciparum and B. bacilliformis. Attachment via MSG1 (GAPDH) protein.Groebel et al. (2009); Zhang et al. (2014c)
M. bovisSmall cell wall-less bacterium that contributes to a number of chronic inflammatory diseases in dairy and feedlot cattle.Undetermined.van der Merwe, Prysliak and Perez-Casal (2010)
M. gallisepticumMycoplasmas are small cell wall-less prokaryotes.Not known.Vogl et al. (2008)
Plasmodium falciparumThe main malaria parasite, part of whose life cycle involves inhabiting RBCs.Recognition of surface receptors precedes a reorientation where the apical end is adjusted to the erythrocyte. A tight junction that involves high-affinity ligand receptor interactions is formed. The tight junction moves from the apical to posterior pole and is powered by the actin-myosin motor of the parasite. The adhesive proteins at the junction are proteolytically removed when the posterior pole is reached, most likely by a rhomboid resident protease in a process that facilitates membrane resealing. The invasion process produces a parasitophorous vacuole containing the merozoite.Cowman and Crabb (2006)
Streptococcus pneumoniaeGram-positive bacterium which causes infection-related diseases.LPXTG motif-containing pneumococcal proteins, erythrocyte lipid rafts and erythrocyte actin remodeling are involved in the invasion mechanism.Yamaguchi et al. (2013)
Theileria sporozitesIntracellular protozoan transmitted by ixodid ticks. Infect wild and domesticated ruminants. Phylogenetically most closely related to Babesia.Occurs in a similar manner to sporozoite entry.Shaw (2003); Bishop et al. (2004)
PathogenType of microorganismMechanism of invasionReferences
Anaplasma marginaleA tick-borne pathogen that causes the disease anaplasmosis in cattle.Via major surface protein 1a (MSP1a)Kocan et al. (2004)
Bartonella bacilliformisB.quintanaBartonella species are fastidious Gram-negative bacteria, which belong to the alpha group of the domain Proteobacteria.The Trw T4SS mediates attachment of Bartonella to red blood cells in Bartonella lineage 4. Bartonella is collected in pits and trenches that form as a result of deformation factor. Invaginations supposedly pinch off to carry the content in a vacuole structure to the cytoplasm of the red blood cell where the organism persists.Iwaki-Egawa and Ihler (1997); Coleman and Minnick (2001); Rolain et al. (2003); Eicher and Dehio (2012)
Brucella melitensisFacultative intracellular Gram-negative coccobacilli.Invasion shown in mouse erythrocytes. Mechanism to be identified.Vitry et al. (2014)
Francisella tularensisHighly infectious bacterium, which can cause severe disease tularemia with an infection of fewer than 10 bacteriaVia serum complement-dependent and independent mechanisms.Conlan (2011); Horzempa et al. (2011)
Mycoplasma suisA member or the hemotrophic mycoplasma group that parasitize erythrocytes in pigs.Invasion occurs in a similar manner to that of P. falciparum and B. bacilliformis. Attachment via MSG1 (GAPDH) protein.Groebel et al. (2009); Zhang et al. (2014c)
M. bovisSmall cell wall-less bacterium that contributes to a number of chronic inflammatory diseases in dairy and feedlot cattle.Undetermined.van der Merwe, Prysliak and Perez-Casal (2010)
M. gallisepticumMycoplasmas are small cell wall-less prokaryotes.Not known.Vogl et al. (2008)
Plasmodium falciparumThe main malaria parasite, part of whose life cycle involves inhabiting RBCs.Recognition of surface receptors precedes a reorientation where the apical end is adjusted to the erythrocyte. A tight junction that involves high-affinity ligand receptor interactions is formed. The tight junction moves from the apical to posterior pole and is powered by the actin-myosin motor of the parasite. The adhesive proteins at the junction are proteolytically removed when the posterior pole is reached, most likely by a rhomboid resident protease in a process that facilitates membrane resealing. The invasion process produces a parasitophorous vacuole containing the merozoite.Cowman and Crabb (2006)
Streptococcus pneumoniaeGram-positive bacterium which causes infection-related diseases.LPXTG motif-containing pneumococcal proteins, erythrocyte lipid rafts and erythrocyte actin remodeling are involved in the invasion mechanism.Yamaguchi et al. (2013)
Theileria sporozitesIntracellular protozoan transmitted by ixodid ticks. Infect wild and domesticated ruminants. Phylogenetically most closely related to Babesia.Occurs in a similar manner to sporozoite entry.Shaw (2003); Bishop et al. (2004)

For the current paper, we have revisited our AD and PD samples and figures from Pretorius et al. (2014a) and Lipinski and Pretorius (2013) and noted the prevalence of bacteria in almost all of the AD and PD samples, in numbers much in excess of those seen in our database of thousands micrographs from healthy individuals. Here we show additional micrographs from the previously published samples (see Figs 5 and 6). In both conditions (see Figs 5AD and 6PD), microbes were noted in close proximity to RBCs, and in some cases RBCs extended pseudopodia-like projections towards the microbiota. SEM analysis of AD whole blood (Fig. 5) shows that mostly coccus-shaped bacteria are present. White blood cells are seen in close proximity to these bacteria in AD patients (see Fig. 5A–C). SEM analyses of PD patients (Fig. 6) show both coccus- and bacillus-shaped bacteria in close proximity to RBCs. We also observed that RBCs extend pseudopodia towards these bacteria and this might be part of the mechanism by which the bacteria enter the RBCs (see Fig. 6C–F). We also note possibly dividing coccus-shaped bacteria in both these conditions, indicated with blue arrows on Fig. 5A (AD patient) and Fig. 6D (PD patient). This might suggest that these bacteria may be(come) culturable under appropriate conditions (see also Soina et al.2012; Epstein 2013).

RBCs with microbiota from patients with diagnosed AD (additional micrographs from sample used in Lipinski and Pretorius 2013). These micrographs are representative of bacteria found in smears of 14 of the 30 AD individuals. (A and B) coccus-shaped bacteria associated with white blood cell; (B) coccus-shaped bacteria associated with an erythrocyte and white blood cell; (C) two white blood cells associated with coccus-shaped bacteria; (D) a string of cocci-blue arrow shows possibly dividing coccoid bacteria; (E) an erythrocyte associated with coccus-shaped bacteria; (F) a high machine magnification of a coccus-shaped bacteria associated with a dense matted fibrin deposit. Scale bar: 1 μm.
Figure 5.

RBCs with microbiota from patients with diagnosed AD (additional micrographs from sample used in Lipinski and Pretorius 2013). These micrographs are representative of bacteria found in smears of 14 of the 30 AD individuals. (A and B) coccus-shaped bacteria associated with white blood cell; (B) coccus-shaped bacteria associated with an erythrocyte and white blood cell; (C) two white blood cells associated with coccus-shaped bacteria; (D) a string of cocci-blue arrow shows possibly dividing coccoid bacteria; (E) an erythrocyte associated with coccus-shaped bacteria; (F) a high machine magnification of a coccus-shaped bacteria associated with a dense matted fibrin deposit. Scale bar: 1 μm.

RBCs with microbiota from patients with diagnosed PD (additional micrographs from sample used in Pretorius et al.2014a). These micrographs are representative of bacteria found in smears of 21 of the 30 PD individuals. (A) A collection of coccus- and bacillus-shaped bacteria; (B) coccus- and bacillus-shaped bacteria associated with erythrocyte; (C) bacillus-shaped bacteria in close proximity with erythrocyte. Erythrocyte forms extensions towards bacteria; (D and E) bacillus-shaped bacteria associated with elongated erythrocytes; (F) coccus- and bacillus-shaped bacteria close to erythrocyte that extends pseudopodia towards the bacteria. Coccus-shaped bacteria shown with pink arrows; bacillus-shaped bacteria shown with white arrows. Dividing coccus-shaped bacteria shown with blue arrow. Scale bar: 1 μm.
Figure 6.

RBCs with microbiota from patients with diagnosed PD (additional micrographs from sample used in Pretorius et al.2014a). These micrographs are representative of bacteria found in smears of 21 of the 30 PD individuals. (A) A collection of coccus- and bacillus-shaped bacteria; (B) coccus- and bacillus-shaped bacteria associated with erythrocyte; (C) bacillus-shaped bacteria in close proximity with erythrocyte. Erythrocyte forms extensions towards bacteria; (D and E) bacillus-shaped bacteria associated with elongated erythrocytes; (F) coccus- and bacillus-shaped bacteria close to erythrocyte that extends pseudopodia towards the bacteria. Coccus-shaped bacteria shown with pink arrows; bacillus-shaped bacteria shown with white arrows. Dividing coccus-shaped bacteria shown with blue arrow. Scale bar: 1 μm.

TEM analysis of the samples from Lipinski and Pretorius (2013) and Pretorius et al. (2014a) showed the presence inside RBCs of cells that appeared to be microbial in nature (unpublished data). These internalized cells further provide evidence for a sustained presence of such a blood microbiota (and one hardly explained by contamination) (see Fig. 7A and B: AD and C and D: PD). Bacteria are shown with arrows in the micrographs. No bacterial membrane was noted; therefore, the bacteria may be L-forms. There seems to be bacterial species selectivity for a given disease, as our preliminary observations suggest a prevalence for bacillus-type bacteria in AD, but both coccus- and bacillus-shaped bacteria in PD patients.

TEM confirming the presence of bacteria inside erythrocytes of (A and B) AD, (C and D) PD. (Additional micrographs from sample used in Lipinski and Pretorius (2013) and Pretorius et al. (2014a). Arrows in each micrograph show the presence of cellular inclusions, without visible membranes. Inclusions are not typically noted in erythrocytes. We suggest that these inclusions are bacteria, possibly as L-forms. Scale bar = 1 μm (A, C, D); 200 nm (D).
Figure 7.

TEM confirming the presence of bacteria inside erythrocytes of (A and B) AD, (C and D) PD. (Additional micrographs from sample used in Lipinski and Pretorius (2013) and Pretorius et al. (2014a). Arrows in each micrograph show the presence of cellular inclusions, without visible membranes. Inclusions are not typically noted in erythrocytes. We suggest that these inclusions are bacteria, possibly as L-forms. Scale bar = 1 μm (A, C, D); 200 nm (D).

Our observations suggest that the presence of bacteria in these two diseases occurs in only a small fraction of the RBC population, which is why we had not really noted them in our previous studies (e.g. Bester et al.2013; Pretorius et al.2013, 2014a,b; Pretorius and Kell 2014), and SEM and TEM analysis confirms this observation. We have never (or not yet) found bacteria inside RBCs from healthy controls (these without overt, diagnosed diseases) when studying blood smears using TEM analysis. The microscopy preparation methods involve a washing process, and this may wash away some of the bacteria, or RBCs and white blood cells associated with bacteria. Therefore, the actual quantification of the bacteria can only be done by other means; however, dormancy and viability versus non-viability issues pertain (as discussed above).

We found a definite association between RBCs and bacteria, with RBCs (see Figs 6 and 7) forming pseudopodia-like extension, as if in the process of engulfing bacteria. Both coccoid (round) and bacillary (elongated) bacteria were found in PD whole blood SEM micrographs, but only coccoid forms in AD whole blood SEM micrographs. Samples from 25 diagnosed AD patients were studied and bacteria were detected in 14 individuals from this AD sample, while samples from 30 PD patients were studied, in 21 of whom we detected bacteria. Obviously, the type of bacteria cannot be identified from ultrastructural observations. As with the timeline of established cases such as the role of H. pylori in ulcers and colon cancer, the next tasks are to bring these microscopically observed bacteria into culture and to carry out sequence-based studies to establish their role (if any) in non-communicable diseases. However, to illustrate that the bacteria may indeed be engulfed by the RBCs, and to confirm that the phenomenon is not due to external contamination, we show TEM micrographs from both of the studied diseases (see Fig. 7, AD and PD).

CONCLUDING REMARKS AND PROSPECTIVE EXPERIMENTS

‘Non-culturable’ (which should be called ‘not-easily-culturable’ or ‘not-yet-cultured’) microbes are commonplace in the ‘environmental microbiology’ of soil and water, and the blood certainly represents an ‘environment’. As we show here, there is a large and scattered literature, increasing in size, to the effect that there might be a (mainly dormant) microbial component in a variety of chronic diseases that are normally considered to be non-microbial or non-communicable in nature, even when microbes appear absent by culturability criteria. Our previous work (e.g. Bester et al.2013; Pretorius et al.2013, 2014a; Kell and Pretorius 2014, 2015; Pretorius and Kell 2014) has implied iron dysregulation as a regular accompaniment to, and probable contributory factor for, a variety of similar diseases, all of which have an inflammatory component. We argue here that there is also a microbial contribution to this in the blood, and it is not unreasonable that the microbial requirement for iron means that, despite the oxidative stress it can entail (Touati 2000; Kell 2009, 2010), microbes may be anticipated to increase in prevalence when iron is free (e.g. Ratledge 2007; Clifton, Corrent and Strong 2009; Sia, Allred and Raymond 2013; Chu et al.2014) and available (D'Onofrio et al.2010), probably behaving in a social manner (Kell, Kaprelyants and Grafen 1995; West and Buckling 2003; Diggle et al.2007; Harrison and Buckling 2009).

We have here pointed up the likelihood of a steady crop of effectively dormant microbes being a feature of blood biology in chronically diseased humans, including those with non-communicable diseases. As with any complex system, the magnitude of any component is affected by the kinetics of every relevant step; while the precise nature of all the interactions is uncertain, Fig. 8 describes the general network—the first step in any systems analysis (Kell 2006; Kell and Knowles 2006).

Relationships between a dormant blood microbiome and chronic disease dyamics.
Figure 8.

Relationships between a dormant blood microbiome and chronic disease dyamics.

Consequently, we recognize that the analysis above has largely been qualitative (the ‘presence’ of a microbial component in a specific disease is a qualitative statement). However, chronic, non-communicable diseases are very far from being static (and thousands of human genes change their expression at least 2-fold even on a diurnal basis; Zhang et al.2014b). Thus, a clear further issue is to seek to understand how the blood microbiome may co-vary with the day-to-day dynamics of chronic diseases. For example, rheumatoid arthritis has circadian rhythms (Straub and Cutolo 2007) and is well known to provide significant variations (‘flares’; Flurey et al.2014) in severity at different times. A reasonable strategy is thus to look for changes in a detectable blood microbiome in this and other diseases that show such flares. As with H. pylori and stomach ulcers (and cancer), the simple prediction is that bactericidal antibiotics should be of value in the treatment of such supposedly non-communicable diseases. Indeed, this prediction is borne out for diseases such as rheumatoid arthritis (Ogrendik 2009a, 2013a; Kwiatkowska and Maślińska 2012) and multiple sclerosis (Ochoa-Repáraz et al.2009; 2011), while antipneumococcal vaccination has shown efficacy in preventing stroke (Vila-Corcoles et al.2014). Of course, events such as heart attacks and strokes (and see Table 4) may also be seen as sudden increases in severity of an underlying condition, and in some cases (such as the much increased likelihood of strokes after subarachnoid haemorrhages; McMahon et al.2013), analysis of changes in the blood microbiome might prove predictive.

The obvious next tasks are thus to relate the number and nature of blood microbes observed in cases such as the above to microbial sequences and antigens that can be detected in aliquots of the same samples (e.g. Salipante et al.2013, 2015), to determine the physiological state of the various microbes (including e.g. whether they are L-forms), and to establish methods to bring them (back) into culture. Since microbes, inflammation and various syndromes are such common co-occurrences (as are coagulopathies; Kell and Pretorius 2015), longitudinal studies will have a specially important role, as they will both show the dynamics and be able to help discriminate cause and effect during the time evolution of chronic, non-communicable diseases in ageing populations. The immunogenicity of persisters, and their ability to induce various kinds of inflammation, must be rather different from that of replicating organisms, and this must be investigated. Armed with such collective knowledge, we might be better placed to develop therapeutics such as pre- and probiotics and bactericidal antibiotics for use in such cases previously thought to lack a microbial contribution.

FUNDING

We thank the Biotechnology and Biological Sciences Research Council (grant BB/L025752/1) as well as the National Research Foundation (NRF) of South Africa for supporting this collaboration.

Conflict of interest. None declared.

GLOSSARY

16S ribosomal RNA: a component of the 30S small subunit of prokaryotic ribosomes. The 16S rRNA gene is found in all bacteria and archaea and consists of nine short hypervariable regions that may be used to distinguish bacterial taxa.

Anabiosis: when an organism is in a state of very low metabolic activity to the extent where it is hardly measurable and in some cases come to a standstill. The physiological and biochemical processes are arrested for different periods of time but can be reversed.

Atopobiosis (Greek |$\mathop {\rm \alpha }\limits^{,{\rm \prime }} {\rm \tau oo\pi o}\varsigma$| or atopos) appearance of the gut or other microbiome in the wrong place.

Bacterial translocation: the passage of viable resident bacteria from the gastrointestinal tract to normally sterile tissues such as the mesenteric lymph nodes and the other internal organs.

Cryptobiosis: refers to latent life or a state where an organism lacks any visible signs of life but is not dead in that it may revert to a state of aliveness as usually defined. Its metabolic activity becomes hardly measurable, or comes reversibly to a standstill.

Culturability: the ability of a cell to reproduce.

Direct viable count: the original method comprises incubation of samples with nutrients (yeast extract) and a single antimicrobial agent that specifically inhibits DNA synthesis but not RNA synthesis (nalidixic acid). Cell division ceases as a result of DNA synthesis inhibition but other cellular metabolic activities remain unaffected and therefore cells continue to metabolize nutrients and grow in size, which allows their detection microscopically in situ.

Dormant: not viable in the sense of not being more or less immediately culturable, but may be returned to a state of viability or culturability by preincubation under suitable conditions.

Dysbiosis: derangement of the species distribution in the normal microbiome.

L-forms: these bacteria are cell wall-deficient forms of normal bacteria. They are able to proliferate as sphaeroplasts or protoplasts under certain conditions.

Metagenomics: direct genetic analysis of a collection of genomes contained in an environmental sample.

Microbiome: the genetic sum of the ecological community of commensal, symbiotic and pathogenic microorganisms that lives on and inside our bodies.

‘Most Probable Number’ technique: is a method used to quantify the concentration of viable microorganisms in a sample. It involves replicate liquid broth growth in 10-fold dilutions. When a dilution lacks growth, it is assumed not to have any organisms. Back-calculation via a Poissonian distribution leads to the ‘most probable number’ in the original sample

Non-axenic culture: contains more than one species, variety or strain of organism.

Non-viable: incapable of observable replication by any stated means normally capable of effecting replication in the relevant organism.

Phylogenetics: a discipline of evolutionary biology that studies the relationships between organisms based on how closely similar some of their macromolecular sequences are.

Pleomorphic: possessing the ability to change shape or size in response to environmental stimuli.

Resuscitation: induction of apparently non-culturable cells to a state of culturability.

Sterile: refers to an absence of operationally viable organisms.

Viable: capable of observable replication, i.e. culturable, by any stated means.

REFERENCES

Aboelatta
YA
Abd-Elsalam
AM
Omar
AH
et al.
Selective digestive decontamination (SDD) as a tool in the management of bacterial translocation following major burns
Ann Burns Fire Disasters
2013
26
182
8

Abrahamsson
TR
Jakobsson
HE
Andersson
AF
et al.
Low diversity of the gut microbiota in infants with atopic eczema
J Allergy Clin Immun
2012
129
434
40
440 e431–32

Abrahamsson
TR
Jakobsson
HE
Andersson
AF
et al.
Low gut microbiota diversity in early infancy precedes asthma at school age
Clin Exp Allergy
2014
44
842
50

Abrahamsson
TR
Wu
RY
Jenmalm
MC
Gut microbiota and allergy: the importance of the pregnancy period
Pediatr Res
2015
77
214
9

Adams
JB
Johansen
LJ
Powell
LD
et al.
Gastrointestinal flora and gastrointestinal status in children with autism—comparisons to typical children and correlation with autism severity
BMC Gastroenterol
2011
11
22

Alam
MZ
Alam
Q
Kamal
MA
et al.
A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer's disease pathogenicity: an update
CNS Neurol Disord-Dr
2014
13
383
90

Allan
EJ
Hoischen
C
Gumpert
J
Bacterial L-forms
Adv Appl Microbiol
2009
68
1
39

Allen
SJ
Gastrointestinal complications and cardiac surgery
J Extra-Corp Technol
2014
46
142
9

Allen-Vercoe
E
Bringing the gut microbiota into focus through microbial culture: recent progress and future perspective
Curr Opin Microbiol
2013
16
625
9

Almenoff
PL
Johnson
A
Lesser
M
et al.
Growth of acid fast L forms from the blood of patients with sarcoidosis
Thorax
1996
51
530
3

Amann
RI
Ludwig
W
Schleifer
KH
Phylogenetic identification and in situ detection of individual microbial cells without cultivation
Microbiol Rev
1995
59
143
69

Amar
J
Lange
C
Payros
G
et al.
Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study
PLoS One
2013
8
e54461

Amar
J
Serino
M
Lange
C
et al.
Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept
Diabetologia
2011
54
3055
61

Amar
S
Engelke
M
Periodontal innate immune mechanisms relevant to atherosclerosis
Mol Oral Microbiol
2014
DOI:10.1111/omi.12087

Amato
SM
Orman
MA
Brynildsen
MP
Metabolic control of persister formation in Escherichia coli
Mol Cell
2013
50
475
87

Anders
HJ
Andersen
K
Stecher
B
The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease
Kidney Int
2013
83
1010
6

Anthony
RM
Brown
TJ
French
GL
Rapid diagnosis of bacteremia by universal amplification of 23S ribosomal DNA followed by hybridization to an oligonucleotide array
J Clin Microbiol
2000
38
781
8

Aronov
PA
Luo
FJ
Plummer
NS
et al.
Colonic contribution to uremic solutes
J Am Soc Nephrol
2011
22
1769
76

Arumugam
M
Raes
J
Pelletier
E
et al.
Enterotypes of the human gut microbiome
Nature
2011
473
174
80

Bakhtiar
SM
LeBlanc
JG
Salvucci
E
et al.
Implications of the human microbiome in inflammatory bowel diseases
FEMS Microbiol Lett
2013
342
10
7

Bakken
LR
Olsen
RA
The relationship between cell size and viability of soil bacteria
Microb Ecol
1987
13
103
14

Balaban
NQ
Merrin
J
Chait
R
et al.
Bacterial persistence as a phenotypic switch
Science
2004
305
1622
5

Balagopal
A
Philp
FH
Astemborski
J
et al.
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C
Gastroenterology
2008
135
226
33

Balakrishnan
A
Marathe
SA
Joglekar
M
et al.
Bactericidal/permeability increasing protein: a multifaceted protein with functions beyond LPS neutralization
Innate Immun
2013
19
339
47

Balamurugan
R
Mary
RR
Chittaranjan
S
et al.
Low levels of faecal lactobacilli in women with iron-deficiency anaemia in south India
Brit J Nutr
2010
104
931
4

Balzan
S
de Almeida Quadros
C
de Cleva
R
et al.
Bacterial translocation: overview of mechanisms and clinical impact
J Gastroen Hepatol
2007
22
464
71

Bennett
BJ
de Aguiar Vallim
TQ
Wang
Z
et al.
Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation
Cell Metab
2013
17
49
60

Berer
K
Mues
M
Koutrolos
M
et al.
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
Nature
2011
479
538
41

Berg
RD
Bacterial translocation from the gastrointestinal tract
Trends Microbiol
1995
3
149
54

Bergen
WG
Small-intestinal or colonic microbiota as a potential amino acid source in animals
Amino Acids
2014
47
251
8

Bergman
E
Energy contributions of volatile fatty acids from the gastrointestinal tract in various species
Physiol Rev
1990
70
567
90

Bested
AC
Logan
AC
Selhub
EM
Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III - convergence toward clinical trials
Gut Pathog
2013
5
4

Bester
J
Buys
AV
Lipinski
B
et al.
High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease
Front Aging Neurosci
2013
5
00088

Bieghs
V
Trautwein
C
Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease
Hepatobiliary Surg Nutr
2014
3
377
85

Bingham
CO
Moni
M
III
Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions
Curr Opin Rheumatol
2013
25
345
53

Bishop
R
Musoke
A
Morzaria
S
et al.
Theileria: intracellular protozoan parasites of wild and domestic ruminants transmitted by ixodid ticks
Parasitology
2004
129
S271
83

Blaser
M
Bork
P
Fraser
C
et al.
The microbiome explored: recent insights and future challenges
Nat Rev Microbiol
2013
11
213
7

Blaser
MJ
The microbiome revolution
J Clin Invest
2014
124
4162
5

Bowdish
DM
Davidson
DJ
Hancock
R
A re-evaluation of the role of host defence peptides in mammalian immunity
Curr Protein Pept Sc
2005
6
35
51

Bravo
JA
Forsythe
P
Chew
MV
et al.
Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve
P Natl Acad Sci
2011
108
16050
5

Brown
K
DeCoffe
D
Molcan
E
et al.
Diet-induced dysbiosis of the intestinal microbiota and the effects on immunity and disease
Nutrients
2012
4
1095
119

Brusca
SB
Abramson
SB
Scher
JU
Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity
Curr Opin Rheumatol
2014
26
101
7

Bruzzese
E
Callegari
ML
Raia
V
et al.
Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial
PLoS One
2014
9
e87796

Burcelin
R
Serino
M
Chabo
C
et al.
Metagenome and metabolism: the tissue microbiota hypothesis
Diabetes Obes Metab
2013
15
Suppl 3
61
70

Calcott
PH
Calvert
TJ
Characterization of 3’: 5’ -cyclic AMP phosphodiesterase in Klebsiella aerogenes and its role in substrate-accelerated death
J Gen Microbiol
1981
122
313
21

Calcott
PH
Postgate
JR
On substrate-accelerated death in Klebsiella aerogenes
J Gen Microbiol
1972
70
115
22

Cani
PD
Bibiloni
R
Knauf
C
et al.
Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice
Diabetes
2008
57
1470
81

Cani
PD
Osto
M
Geurts
L
et al.
Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity
Gut Microbes
2012
3
279
88

Caporaso
JG
Lauber
CL
Costello
EK
et al.
Moving pictures of the human microbiome
Genome Biol
2011
12
R50

Cardona
F
Andres-Lacueva
C
Tulipani
S
et al.
Benefits of polyphenols on gut microbiota and implications in human health
J Nutr Biochem
2013
24
1415
22

Casadesús
J
Bacterial L-forms require peptidoglycan synthesis for cell division
Bioessays
2007
29
1189
91

Catrina
AI
Deane
KD
Scher
JU
Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis
Rheumatology
2014

Cavanagh
JP
Hjerde
E
Holden
MT
et al.
Whole-genome sequencing reveals clonal expansion of multiresistant Staphylococcus haemolyticus in European hospitals
J Antimicrob Chemoth
2014
69
2920
7

Cénit
MC
Matzaraki
V
Tigchelaar
EF
et al.
Rapidly expanding knowledge on the role of the gut microbiome in health and disease
Biochim Biophys Acta
2014
1842
1981
92

Chang
SS
Hsu
HL
Cheng
JC
et al.
An efficient strategy for broad-range detection of low abundance bacteria without DNA decontamination of PCR reagents
PLoS One
2011
6
e20303

Chen
P
Schnabl
B
Host-microbiome interactions in alcoholic liver disease
Gut Liver
2014
8
237
41

Chien
LN
Chi
NF
Hu
CJ
et al.
Central nervous system infections and stroke—a population-based analysis
Acta Neurol Scand
2013
128
241
8

Cho
I
Blaser
MJ
The human microbiome: at the interface of health and disease
Nat Rev Genet
2012
13
260
70

Chu
BC
Otten
R
Krewulak
KD
et al.
The solution structure, binding properties, and dynamics of the bacterial siderophore-binding protein FepB
J Biol Chem
2014
289
29219
34

Clark
MA
Jepson
MA
Intestinal M cells and their role in bacterial infection
Int J Med Microbiol
2003
293
17
39

Claudi
B
Sprote
P
Chirkova
A
et al.
Phenotypic variation of Salmonella in host tissues delays eradication by antimicrobial chemotherapy
Cell
2014
158
722
33

Clegg
JS
Cryptobiosis—a peculiar state of biological organization
Comp Biochem Phys B
2001
128
613
24

Clemente
JC
Ursell
LK
Parfrey
LW
et al.
The impact of the gut microbiota on human health: an integrative view
Cell
2012
148
1258
70

Clifton
MC
Corrent
C
Strong
RK
Siderocalins: siderophore-binding proteins of the innate immune system
Biometals
2009
22
557
64

Clingenpeel
S
Schwientek
P
Hugenholtz
P
et al.
Effects of sample treatments on genome recovery via single-cell genomics
ISME J
2014
8
2546
9

Coleman
SA
Minnick
MF
Establishing a direct role for the Bartonella bacilliformis invasion-associated locus B (IalB) protein in human erythrocyte parasitism
Infect Immun
2001
69
4373
81

Conlan
JW
Francisella tularensis: a red-blooded pathogen
J Infect Dis
2011
204
6
8

Conte
MP
Schippa
S
Zamboni
I
et al.
Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease
Gut
2006
55
1760
7

Cooke
G
Behan
J
Costello
M
Newly identified vitamin K-producing bacteria isolated from the neonatal faecal flora
Microb Ecol Health D
2006
18
133
8

Corr
SC
Gahan
CC
Hill
C
M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis
FEMS Immunol Med Mic
2008
52
2
12

Cowman
AF
Crabb
BS
Invasion of red blood cells by malaria parasites
Cell
2006
124
755
66

Craciun
S
Balskus
EP
Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme
P Natl Acad Sci USA
2012
109
21307
12

Dalager-Pedersen
M
Sogaard
M
Schonheyder
HC
et al.
Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study
Circulation
2014
129
1387
96

Davey
HM
Kell
DB
Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses
Microbiol Rev
1996
60
641
96

De Angelis
M
Piccolo
M
Vannini
L
et al.
Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified
PLoS One
2013
8
e76993

de Goffau
MC
Fuentes
S
van den Bogert
B
et al.
Aberrant gut microbiota composition at the onset of type 1 diabetes in young children
Diabetologia
2014
57
1569
77

De Preter
V
Verbeke
K
Metabolomics as a diagnostic tool in gastroenterology
World J Gastrointest Pharmacol Ther
2013
4
97
107

Dedysh
SN
Cultivating uncultured bacteria from northern wetlands: knowledge gained and remaining gaps
Front Microbiol
2011
2
184

Degnan
PH
Taga
ME
Goodman
AL
Vitamin B12 as a modulator of gut microbial ecology
Cell Metab
2014
20
769
78

Deitch
EA
Gut-origin sepsis: evolution of a concept
Surgeon
2012
10
350
6

Delzenne
NM
Cani
PD
Interaction between obesity and the gut microbiota: relevance in nutrition
Annu Rev Nutr
2011
31
15
31

Delzenne
NM
Neyrinck
AM
Bäckhed
F
et al.
Targeting gut microbiota in obesity: effects of prebiotics and probiotics
Nat Rev Endocrinol
2011
7
639
46

Demoruelle
MK
Deane
KD
Holers
VM
When and where does inflammation begin in rheumatoid arthritis?
Curr Opin Rheumatol
2014
26
64
71

den Besten
G
van Eunen
K
Groen
AK
et al.
The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism
J Lipid Res
2013
54
2325
40

Desbonnet
L
Garrett
L
Clarke
G
et al.
The probiotic Bifidobacteria infantis: an assessment of potential antidepressant properties in the rat
J Psychiatr Res
2008
43
164
74

Detert
J
Pischon
N
Burmester
GR
et al.
The association between rheumatoid arthritis and periodontal disease
Arthritis Res Ther
2010
12
218

Devaraj
S
Hemarajata
P
Versalovic
J
The human gut microbiome and body metabolism: implications for obesity and diabetes
Clin Chem
2013
59
617
28

Devine
KM
Bacterial L-forms on tap: an improved methodology to generate Bacillus subtilis L-forms heralds a new era of research
Mol Microbiol
2012
83
10
3

Didelot
X
Bowden
R
Wilson
DJ
et al.
Transforming clinical microbiology with bacterial genome sequencing
Nat Rev Genet
2012
13
601
12

Diggle
SP
Griffin
AS
Campbell
GS
et al.
Cooperation and conflict in quorum-sensing bacterial populations
Nature
2007
450
411
4

Dinakaran
V
Rathinavel
A
Pushpanathan
M
et al.
Elevated levels of circulating DNA in cardiovascular disease patients: metagenomic profiling of microbiome in the circulation
PLoS One
2014
9
e105221

Ding
PH
Jin
LJ
The role of lipopolysaccharide-binding protein in innate immunity: a revisit and its relevance to oral/periodontal health
J Periodontal Res
2014
49
1
9

Ding
T
Schloss
PD
Dynamics and associations of microbial community types across the human body
Nature
2014
509
357
60

Domingue
GJ
Demystifying pleomorphic forms in persistence and expression of disease: Are they bacteria, and is peptidoglycan the solution?
Discov Med
2010
10
234
46

Domingue
GJ
Schlegel
JU
Novel bacterial structures in human blood: cultural isolation
Infect Immun
1977
15
621
7

Domingue
GJ
Sr
Woody
HB
Bacterial persistence and expression of disease
Clin Microbiol Rev
1997
10
320
44

Domínguez-Cuevas
P
Mercier
R
Leaver
M
et al.
The rod to L-form transition of Bacillus subtilis is limited by a requirement for the protoplast to escape from the cell wall sacculus
Mol Microbiol
2012
83
52
66

D'Onofrio
A
Crawford
JM
Stewart
EJ
et al.
Siderophores from neighboring organisms promote the growth of uncultured bacteria
Chem Biol
2010
17
254
64

Dostal
A
Baumgartner
J
Riesen
N
et al.
Effects of iron supplementation on dominant bacterial groups in the gut, faecal SCFA and gut inflammation: a randomised, placebo-controlled intervention trial in South African children
Brit J Nutr
2014
112
547
56

Dostal
A
Chassard
C
Hilty
FM
et al.
Iron depletion and repletion with ferrous sulfate or electrolytic iron modifies the composition and metabolic activity of the gut microbiota in rats
J Nutr
2012
142
271
7

Dowd
SE
Sun
Y
Secor
PR
et al.
Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing
BMC Microbiol
2008
8
43

Drennan
M
What is ‘Sterile Blood’?
Brit Med J
1942
2
526

Duda
VI
Suzina
NE
Polivtseva
VN
et al.
Ultramicrobacteria: formation of the concept and contribution of ultramicrobacteria to biology
Mikrobiologiia
2012
81
415
27

Duytschaever
G
Huys
G
Bekaert
M
et al.
Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings
Appl Environ Microb
2011
77
8015
24

Duytschaever
G
Huys
G
Bekaert
M
et al.
Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota
J Cyst Fibros
2013
12
206
15

Ebringer
A
Rashid
T
Rheumatoid arthritis is caused by a Proteus urinary tract infection
APMIS
2014
122
363
8

Eicher
SC
Dehio
C
Bartonella entry mechanisms into mammalian host cells
Cell Microbiol
2012
14
1166
73

Eilers
H
Pernthaler
J
Glockner
FO
et al.
Culturability and In situ abundance of pelagic bacteria from the North Sea
Appl Environ Microb
2000
66
3044
51

Eisenreich
W
Dandekar
T
Heesemann
J
et al.
Carbon metabolism of intracellular bacterial pathogens and possible links to virulence
Nat Rev Microbiol
2010
8
401
12

Eleftheriadis
T
Liakopoulos
V
Leivaditis
K
et al.
Infections in hemodialysis: a concise review—Part 1: bacteremia and respiratory infections
Hippokratia
2011
15
12
7

ElRakaiby
M
Dutilh
BE
Rizkallah
MR
et al.
Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics
Omics
2014
18
402
14

Emsley
HC
Chamorro
A
Stroke bugs: current and emerging concepts relevant to infection in cerebrovascular disease
Infect Disord Drug Targets
2010
10
65
6

Emsley
HC
Hopkins
SJ
Acute ischaemic stroke and infection: recent and emerging concepts
Lancet Neurol
2008
7
341
53

Emsley
HC
Smith
CJ
Gavin
CM
et al.
An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis
J Neuroimmunol
2003
139
93
101

Emsley
HC
Tyrrell
PJ
Inflammation and infection in clinical stroke
J Cerebr Blood F Met
2002
22
1399
419

Epstein
SE
Zhou
YF
Zhu
J
Infection and atherosclerosis: emerging mechanistic paradigms
Circulation
1999
100
e20
8

Epstein
SE
Zhu
J
Najafi
AH
et al.
Insights into the role of infection in atherogenesis and in plaque rupture
Circulation
2009
119
3133
41

Epstein
SS
The phenomenon of microbial uncultivability
Curr Opin Microbiol
2013
16
636
42

Erridge
C
The roles of pathogen-associated molecular patterns in atherosclerosis
Trends Cardiovas Med
2008
18
52
6

Errington
J
L-form bacteria, cell walls and the origins of life
Open Biol
2013
3
120143

Everard
A
Matamoros
S
Geurts
L
et al.
Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice
MBio
2014
5
e01011
4

Faure
M
Mettraux
C
Moennoz
D
et al.
Specific amino acids increase mucin synthesis and microbiota in dextran sulfate sodium-treated rats
J Nutr
2006
136
1558
64

Feeley
JC
Gorman
GW
Weaver
RE
et al.
Primary isolation media for Legionnaires disease bacterium
J Clin Microbiol
1978
8
320
5

Fernández-Cruz
A
Marin
M
Kestler
M
et al.
The value of combining blood culture and SeptiFast data for predicting complicated bloodstream infections caused by Gram-positive bacteria or Candida species
J Clin Microbiol
2013
51
1130
6

Festi
D
Schiumerini
R
Eusebi
LH
et al.
Gut microbiota and metabolic syndrome
World J Gastroenterol
2014
20
16079
94

Finegold
SM
Dowd
SE
Gontcharova
V
et al.
Pyrosequencing study of fecal microflora of autistic and control children
Anaerobe
2010
16
444
53

Flores
GE
Caporaso
JG
Henley
JB
et al.
Temporal variability is a personalized feature of the human microbiome
Genome Biol
2014
15
531

Flurey
CA
Morris
M
Richards
P
et al.
It's like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes
Rheumatology
2014
53
696
703

Fredricks
DN
The Human Microbiota: How Microbial Communities Affect Health and Disease
2013
Hoboken, NJ
Wiley

Fremont
M
Coomans
D
Massart
S
et al.
High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients
Anaerobe
2013
22
50
6

French
AL
Evans
CT
Agniel
DM
et al.
Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus
J Infect Dis
2013
208
679
89

Fricke
WF
Rasko
DA
Bacterial genome sequencing in the clinic: bioinformatic challenges and solutions
Nat Rev Genet
2014
15
49
55

Fugate
JE
Lyons
JL
Thakur
KT
et al.
Infectious causes of stroke
Lancet Infect Dis
2014
14
869
80

Fukuda
S
Hase
K
Ohno
H
Application of a mouse ligated Peyer's patch intestinal loop assay to evaluate bacterial uptake by M cells
J Vis Exp
2011
e3225
30

Gaibani
P
Mariconti
M
Bua
G
et al.
Development of a broad-range 23S rDNA real-time PCR assay for the detection and quantification of pathogenic bacteria in human whole blood and plasma specimens
Biomed Res Int
2013
2013
264651

Gérard
P
Metabolism of cholesterol and bile acids by the gut microbiota
Pathogens
2013
3
14
24

Gerdes
K
Maisonneuve
E
Bacterial persistence and toxin-antitoxin loci
Annu Rev Microbiol
2012
66
103
23

Germain
E
Castro-Roa
D
Zenkin
N
et al.
Molecular mechanism of bacterial persistence by HipA
Mol Cell
2013
52
248
54

Gest
H
The Modern Myth of ‘Unculturable’ Bacteria: Scotoma of Contemporary Microbiology
2008
Faculty Research (Bloomington)
http://hdl.handle.net/2022/3149 (19 March 2015, date last accessed)

Geurts
L
Neyrinck
AM
Delzenne
NM
et al.
Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics
Benef Microbes
2014
5
3
17

Giannelli
V
DiGregorio
V
Iebba
V
et al.
Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis
World J Gastroenterol
2014
20
16795
810

Gich
F
Schubert
K
Bruns
A
et al.
Specific detection, isolation, and characterization of selected, previously uncultured members of the freshwater bacterioplankton community
Appl Environ Microb
2005
71
5908
19

Glaros
TG
Chang
S
Gilliam
EA
et al.
Causes and consequences of low grade endotoxemia and inflammatory diseases
Front Biosci
2013
5
754
65

Gonzalez
A
Stombaugh
J
Lozupone
C
et al.
The mind-body-microbial continuum
Dialogues Clin Neurosci
2011
13
55
62

Grau
AJ
Urbanek
C
Palm
F
Common infections and the risk of stroke
Nat Rev Neurol
2010
6
681
94

Gribbin
JR
In Search of Schrödinger's Cat: Quantum Physics and Reality
1985
London
Bantam Books

Grif
K
Fille
M
Würzner
R
et al.
Rapid detection of bloodstream pathogens by real-time PCR in patients with sepsis
Wien Klin Wochenschr
2012a
124
266
70

Grif
K
Heller
I
Prodinger
WM
et al.
Improvement of detection of bacterial pathogens in normally sterile body sites with a focus on orthopedic samples by use of a commercial 16S rRNA broad-range PCR and sequence analysis
J Clin Microbiol
2012b
50
2250
4

Groebel
K
Hoelzle
K
Wittenbrink
MM
et al.
Mycoplasma suis invades porcine erythrocytes
Infect Immun
2009
77
576
84

Guo
ZZ
Wang
P
Yi
ZH
et al.
The crosstalk between gut inflammation and gastrointestinal disorders during acute pancreatitis
Curr Pharm Des
2014
20
1051
62

Harrison
F
Buckling
A
Cooperative production of siderophores by Pseudomonas aeruginosa
Front Biosci
2009
14
4113
26

Havey
TC
Fowler
RA
Daneman
N
Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis
Crit Care
2011
15
R267

Hevia
A
Milani
C
Lopez
P
et al.
Intestinal dysbiosis associated with systemic lupus erythematosus
MBio
2014
5
e01548
14

Hill
MJ
Intestinal flora and endogenous vitamin synthesis
Eur J Cancer Prev
1997
6
Suppl 1
S43
5

Hold
GL
Smith
M
Grange
C
et al.
Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?
World J Gastroenterol
2014
20
1192
210

Holden
DW
Microbiology. Persisters unmasked
Science
2015
347
30
2

Holmes
E
Li
JV
Athanasiou
T
et al.
Understanding the role of gut microbiome-host metabolic signal disruption in health and disease
Trends Microbiol
2011
19
349
59

Hopkins
PN
Molecular biology of atherosclerosis
Physiol Rev
2013
93
1317
542

Horzempa
J
O'Dee
DM
Stolz
DB
et al.
Invasion of erythrocytes by Francisella tularensis
J Infect Dis
2011
204
51
9

Huang
Y
Fan
XG
Tang
ZS
et al.
Detection of Helicobacter pylori DNA in peripheral blood from patients with peptic ulcer or gastritis
APMIS
2006
114
851
6

Hugenholtz
P
Exploring prokaryotic diversity in the genomic era
Genome Biol
2002
3
0003.1–0003.8

Isberg
RR
Discrimination between intracellular uptake and surface adhesion of bacterial pathogens
Science
1991
252
934
8

Iwaki-Egawa
S
Ihler
GM
Comparison of the abilities of proteins from Bartonella bacilliformis and Bartonella henselae to deform red cell membranes and to bind to red cell ghost proteins
FEMS Microbiol Lett
1997
157
207
17

Jepson
MA
Clark
MA
Studying M cells and their role in infection
Trends Microbiol
1998
6
359
65

Jiang
W
Lederman
MM
Hunt
P
et al.
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection
J Infect Dis
2009
199
1177
85

Joyce
SA
MacSharry
J
Casey
PG
et al.
Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut
P Natl Acad Sci USA
2014
111
7421
6

Jun
DW
Kim
KT
Lee
OY
et al.
Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients
Dig Dis Sci
2010
55
1465
71

Jung
C
Hugot
JP
Barreau
F
Peyer's patches: the immune sensors of the intestine
Int J Inflam
2010
2010
823710

Kahle
K
Kraus
M
Scheppach
W
et al.
Studies on apple and blueberry fruit constituents: do the polyphenols reach the colon after ingestion?
Mol Nutr Food Res
2006
50
418
23

Kakiyama
G
Pandak
WM
Gillevet
PM
et al.
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis
J Hepatol
2013
58
949
55

Kamagata
Y
Tamaki
H
Cultivation of uncultured fastidious microbes
Microbes Environ
2005
20
85
91

Kang
DW
Park
JG
Ilhan
ZE
et al.
Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children
PLoS One
2013
8
e68322

Kaprelyants
AS
Gottschal
JC
Kell
DB
Dormancy in non-sporulating bacteria
FEMS Microbiol Rev
1993
10
271
85

Kaprelyants
AS
Kell
DB
Dormancy in stationary-phase cultures of Micrococcus luteus: flow cytometric analysis of starvation and resuscitation
Appl Environ Microb
1993
59
3187
96

Kaprelyants
AS
Mukamolova
GV
Davey
HM
et al.
Quantitative analysis of the physiological heterogeneity within starved cultures of Micrococcus luteus by flow cytometry and cell sorting
Appl Environ Microb
1996
62
1311
6

Kaprelyants
AS
Mukamolova
GV
Kell
DB
Estimation of dormant Micrococcus luteus cells by penicillin lysis and by resuscitation in cell-free spent medium at high dilution
FEMS Microbiol Lett
1994
115
347
52

Kaprelyants
AS
Mukamolova
GV
Kormer
SS
et al.
Intercellular signalling and the multiplication of prokaryotes: bacterial cytokines
Symp Soc Gen Microbi
1999
57
33
69

Karlsson
FH
Fak
F
Nookaew
I
et al.
Symptomatic atherosclerosis is associated with an altered gut metagenome
Nat Commun
2012
3
1245

Karlsson
FH
Tremaroli
V
Nookaew
I
et al.
Gut metagenome in European women with normal, impaired and diabetic glucose control
Nature
2013
498
99
103

Karri
S
Martinez
VA
Coimbatore
G
Effect of dihydrotestosterone on gastrointestinal tract of male Alzheimer's disease transgenic mice
2010
48
453
65

Kau
AL
Ahern
PP
Griffin
NW
et al.
Human nutrition, the gut microbiome and the immune system
Nature
2011
474
327
36

Keilin
D
The problem of anabiosis or latent life: history and current concept
P Roy Soc Lond B Bio
1959
150
149
91

Kell
DB
Metabolomics, modelling and machine learning in systems biology: towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture
FEBS J
2006
273
873
94

Kell
DB
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases
BMC Med Genomics
2009
2
2

Kell
DB
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples
Arch Toxicol
2010
84
825
89

Kell
DB
Kaprelyants
AS
Grafen
A
Pheromones, social behaviour and the functions of secondary metabolism in bacteria
Trends Ecol Evol
1995
10
126
9

Kell
DB
Kaprelyants
AS
Weichart
DH
et al.
Viability and activity in readily culturable bacteria: a review and discussion of the practical issues
Anton Leeuw
1998
73
169
87

Kell
DB
Knowles
JD
Szallasi
Z
Stelling
J
Periwal
V
The role of modeling in systems biology
System Modeling in Cellular Biology: From Concepts to Nuts and Bolts
2006
Cambridge
MIT Press
3
18

Kell
DB
Mukamolova
GV
Finan
CL
Bull
AT
et al.
Resuscitation of ‘uncultured’ microorganisms
Microbial Diversity and Bioprospecting
2003
Washington, DC
American Society for Microbiology
100
8

Kell
DB
Oliver
SG
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion
Front Pharmacol
2014
5
231

Kell
DB
Pretorius
E
Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells
Metallomics
2014
4
748
73

Kell
DB
Pretorius
E
The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen)
Integr Biol
2015
7
24
52

Kell
DB
Ryder
HM
Kaprelyants
AS
et al.
Quantifying heterogeneity: flow cytometry of bacterial cultures
Anton Leeuw
1991
60
145
58

Keller
M
Zengler
K
Tapping into microbial diversity
Nat Rev Microbiol
2004
2
141
50

Keren
I
Kaldalu
N
Spoering
A
et al.
Persister cells and tolerance to antimicrobials
FEMS Microbiol Lett
2004a
230
13
8

Keren
I
Shah
D
Spoering
A
et al.
Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli
J Bacteriol
2004b
186
8172
80

Kernéis
S
Bogdanova
A
Kraehenbuhl
JP
et al.
Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria
Science
1997
277
949
52

Kibru
D
Gelaw
B
Alemu
A
et al.
Helicobacter pylori infection and its association with anemia among adult dyspeptic patients attending Butajira Hospital, Ethiopia
BMC Infect Dis
2014
14
656

Kimura
I
Ozawa
K
Inoue
D
et al.
The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43
Nat Commun
2013
4
1829

Kinoshita
M
Takeda
K
Microbial and dietary factors modulating intestinal regulatory T cell homeostasis
FEBS Lett
2014
588
4182
7

Kishino
S
Takeuchi
M
Park
S-B
et al.
Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition
P Natl Acad Sci USA
2013
110
17808
13

Klatt
NR
Funderburg
NT
Brenchley
JM
Microbial translocation, immune activation, and HIV disease
Trends Microbiol
2013
21
6
13

Kocan
KM
de la Fuente
J
Blouin
EF
et al.
Anaplasma marginale (Rickettsiales: Anaplasmataceae): recent advances in defining host-pathogen adaptations of a tick-borne rickettsia
Parasitology
2004
129
Suppl
285
300

Koch
AL
The adaptive responses of Escherichia coli to a feast and famine existence
Adv Microb Physiol
1971
6
147
217

Koch
AL
Neidhardt
FC
et al.
The variability and individuality of the bacterium
Escherichia coli and Salmonella Typhimurium: Cellular and Molecular Biology
1987
Washington, DC
American Society for Microbiology
1606
14

Koeth
RA
Wang
Z
Levison
BS
et al.
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis
Nat Med
2013
19
576
85

Kogure
K
Simidu
U
Taga
N
A tentative direct microscopic method for counting living marine bacteria
Can J Microbiol
1979
25
415
20

Koren
O
Knights
D
Gonzalez
A
et al.
A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets
PLoS Comput Biol
2013
9
e1002863

Koren
O
Spor
A
Felin
J
et al.
Human oral, gut, and plaque microbiota in patients with atherosclerosis
P Natl Acad Sci USA
2011
108
4592
8

Kostic
AD
Xavier
RJ
Gevers
D
The microbiome in inflammatory bowel disease: current status and the future ahead
Gastroenterology
2014
146
1489
99

Kotsaki
A
Giamarellos-Bourboulis
EJ
Emerging drugs for the treatment of sepsis
Expert Opin Emerg Dr
2012
17
379
91

Kozarov
E
Sweier
D
Shelburne
C
et al.
Detection of bacterial DNA in atheromatous plaques by quantitative PCR
Microbes Infect
2006
8
687
93

Koziel
J
Mydel
P
Potempa
J
The link between periodontal disease and rheumatoid arthritis: an updated review
Curr Rheumatol Rep
2014
16
408

Kwiatkowska
B
Maślińska
M
Macrolide therapy in chronic inflammatory diseases
Mediat Inflamm
2012
2012
636157

Kyrpides
NC
Hugenholtz
P
Eisen
JA
et al.
Genomic encyclopedia of bacteria and archaea: sequencing a myriad of type strains
PLoS Biol
2014
12
1001920

Lagier
JC
Edouard
S
Pagnier
I
et al.
Current and past strategies for bacterial culture in clinical microbiology
Clin Microbiol Rev
2015a
28
208
36

Lagier
JC
Hugon
P
Khelaifia
S
et al.
The rebirth of culture in microbiology through the example of culturomics to study human gut microbiota
Clin Microbiol Rev
2015b
28
237
64

Lanter
BB
Sauer
K
Davies
DG
Bacteria present in carotid arterial plaques are found as biofilm deposits which may contribute to enhanced risk of plaque rupture
MBio
2014
5
e01206
14

Larsen
N
Vogensen
FK
van den Berg
FW
et al.
Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults
PLoS One
2010
5
e9085

Lasken
RS
Genomic sequencing of uncultured microorganisms from single cells
Nat Rev Microbiol
2012
10
631
40

Lasken
RS
McLean
JS
Recent advances in genomic DNA sequencing of microbial species from single cells
Nat Rev Genet
2014
15
577
84

Le Chatelier
E
Nielsen
T
Qin
J
et al.
Richness of human gut microbiome correlates with metabolic markers
Nature
2013
500
541
6

LeBlanc
JG
Milani
C
de Giori
GS
et al.
Bacteria as vitamin suppliers to their host: a gut microbiota perspective
Curr Opin Biotechnol
2013
24
160
8

Leli
C
Cardaccia
A
Ferranti
M
et al.
Procalcitonin better than C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in predicting DNAemia in patients with sepsis
Scand J Infect Dis
2014
46
745
52

Lelouard
H
Henri
S
De Bovis
B
et al.
Pathogenic bacteria and dead cells are internalized by a unique subset of Peyer's patch dendritic cells that express lysozyme
Gastroenterology
2010
138
173
e171
84
73

Leslie
JL
Young
VB
The rest of the story: the microbiome and gastrointestinal infections
Curr Opin Microbiol
2015
23c
121
5

Lewis
K
Persister cells
Annu Rev Microbiol
2010
64
357
72

Lin
W
Weinberg
EM
Chung
RT
Pathogenesis of accelerated fibrosis in HIV/HCV co-infection
J Infect Dis
2013
207
Suppl 1
S13
8

Ling
LL
Schneider
T
Peoples
AJ
et al.
A new antibiotic kills pathogens without detectable resistance
Nature
2015
517
455
9

Lipinski
B
Pretorius
E
The role of iron-induced fibrin in the pathogenesis of Alzheimer's disease and the protective role of magnesium
Front Hum Neurosci
2013
7
735

Loman
NJ
Constantinidou
C
Chan
JZ
et al.
High-throughput bacterial genome sequencing: an embarrassment of choice, a world of opportunity
Nat Rev Microbiol
2012
10
599
606

Lozupone
CA
Li
M
Campbell
TB
et al.
Alterations in the gut microbiota associated with HIV-1 infection
Cell Host Microbe
2013
14
329
39

Lozupone
CA
Stombaugh
JI
Gordon
JI
et al.
Diversity, stability and resilience of the human gut microbiota
Nature
2012
489
220
30

Luckey
D
Gomez
A
Murray
J
et al.
Bugs, us: the role of the gut in autoimmunity
Indian J Med Res
2013
138
732
43

Lysak
LV
Lapygina
EV
Konova
IA
et al.
Quantity and taxonomic composition of ultramicrobacteria in soils
Microbiology
2010
79
408
12

Ma
HD
Wang
YH
Chang
C
et al.
The intestinal microbiota and microenvironment in liver
Autoimmun Rev
2015
14
183
91

McColl
BW
Allan
SM
Rothwell
NJ
Systemic infection, inflammation and acute ischemic stroke
Neuroscience
2009
158
1049
61

McDermott
AJ
Huffnagle
GB
The microbiome and regulation of mucosal immunity
Immunology
2014
142
24
31

Macdonell
MT
Hood
MA
Isolation and characterization of ultramicrobacteria from a gulf coast estuary
Appl Environ Microb
1982
43
566
71

MacFie
J
Current status of bacterial translocation as a cause of surgical sepsis
Brit Med Bull
2004
71
1
11

McHardy
IH
Li
X
Tong
M
et al.
HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota
Microbiome
2013
1
26

Macintire
DK
Bellhorn
TL
Bacterial translocation: clinical implications and prevention
Vet Clin N Am-Small
2002
32
1165
78

McLaughlin
RW
Vali
H
Lau
PCK
et al.
Are there naturally occurring pleomorphic bacteria in the blood of healthy humans?
J Clin Microbiol
2002
40
4771
5

McMahon
CJ
Hopkins
S
Vail
A
et al.
Inflammation as a predictor for delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage
J Neurointerv Surg
2013
5
512
7

Madan
JC
Koestler
DC
Stanton
BA
et al.
Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures
MBio
2012
3
e00251–12

Maisonneuve
E
Castro-Camargo
M
Gerdes
K
(p)ppGpp controls bacterial persistence by stochastic induction of toxin-antitoxin activity
Cell
2013
154
1140
50

Maisonneuve
E
Gerdes
K
Molecular mechanisms underlying bacterial persisters
Cell
2014
157
539
48

Maiwald
M
Relman
DA
Whipple's disease and Tropheryma whippelii: secrets slowly revealed
Clin Infect Dis
2001
32
457
63

Maiwald
M
von Herbay
A
Fredricks
DN
et al.
Cultivation of Tropheryma whipplei from cerebrospinal fluid
J Infect Dis
2003
188
801
8

Malaguarnera
G
Giordano
M
Nunnari
G
et al.
Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives
World J Gastroenterol
2014
20
16639
48

Mancini
N
Carletti
S
Ghidoli
N
et al.
The era of molecular and other non-culture-based methods in diagnosis of sepsis
Clin Microbiol Rev
2010
23
235
51

Manichanh
C
Borruel
N
Casellas
F
et al.
The gut microbiota in IBD
Nat Rev Gastroentero
2012
9
599
608

Marín
L
Miguélez
EM
Villar
CJ
et al.
Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties
BioMed Res Int
2015
2015
905215

Mariotti
S
Pardini
M
Gagliardi
MC
et al.
Dormant Mycobacterium tuberculosis fails to block phagosome maturation and shows unexpected capacity to stimulate specific human T lymphocytes
J Immunol
2013
191
274
82

Marshall
B
Helicobacter connections
ChemMedChem
2006
1
783
802

Marshall
BJ
Warren
JR
Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration
Lancet
1984
1
1311
5

Martin
F-PJ
Dumas
M-E
Wang
Y
et al.
A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model
Mol Syst Biol
2007
3
112

Martínez
I
Perdicaro
DJ
Brown
AW
et al.
Diet-induced alterations of host cholesterol metabolism are likely to affect the gut microbiota composition in hamsters
Appl Environ Microb
2013
79
516
24

Martínez
I
Wallace
G
Zhang
C
et al.
Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota
Appl Environ Microb
2009
75
4175
84

Maslowski
KM
Vieira
AT
Ng
A
et al.
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Nature
2009
461
1282
6

Mason
CA
Hamer
G
Bryers
JD
The death and lysis of microorganisms in environmental processes
FEMS Microbiol Rev
1986
39
373
401

Mathias
A
Pais
B
Favre
L
et al.
Role of secretory IgA in the mucosal sensing of commensal bacteria
Gut Microbes
2014
5
688
95

Mattman
L
Cell Wall Deficient Forms: Stealth Pathogens
2001
Boca Raton, FL: CRC Press

Mercier
R
Kawai
Y
Errington
J
Excess membrane synthesis drives a primitive mode of cell proliferation
Cell
2013
152
997
1007

Mercier
R
Kawai
Y
Errington
J
General principles for the formation and proliferation of a wall-free (L-form) state in bacteria
Elife
2014
3
e04629

Meyer
RD
Legionella infections: a review of five years of research
Rev Infect Dis
1983
5
258
78

Mifkovic
A
Skultety
J
Pindak
D
et al.
Specific aspects of acute pancreatitis
Bratisl Lek Listy
2009
110
544
52

Mifkovic
A
Skultety
J
Sykora
P
et al.
Intra-abdominal hypertension and acute pancreatitis
Bratisl Lek Listy
2013
114
166
71

Minasyan
H
Erythrocyte and blood antibacterial defense
Eur J Microbiol Immunol
2014
4
138
43

Montassier
E
Batard
E
Gastinne
T
et al.
Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance
Eur J Clin Microbiol
2013
32
841
50

Montes-de-Oca
M
Blanco
MJ
Marquez
M
et al.
Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation
Liver Int
2011
31
850
8

Morgan
XC
Huttenhower
C
Meta'omic analytic techniques for studying the intestinal microbiome
Gastroenterology
2014
146
1437
48

Morgan
XC
Tickle
TL
Sokol
H
et al.
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Genome Biol
2012
13
R79

Morita
RY
Bacteria in Oligotrophic Environments: Starvation-Survival Lifestyle
1997
New York
Chapman and Hall

Muegge
BD
Kuczynski
J
Knights
D
et al.
Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans
Science
2011
332
970
4

Mukamolova
GV
Kaprelyants
AS
Young
DI
et al.
A bacterial cytokine
P Natl Acad Sci USA
1998a
95
8916
21

Mukamolova
GV
Kormer
SS
Kell
DB
et al.
Stimulation of the multiplication of Micrococcus luteus by an autocrine growth factor
Arch Microbiol
1999
172
9
14

Mukamolova
GV
Turapov
OA
Kazarian
K
et al.
The rpf gene of Micrococcus luteus encodes an essential secreted growth factor
Mol Microbiol
2002a
46
611
21

Mukamolova
GV
Turapov
OA
Young
DI
et al.
A family of autocrine growth factors in Mycobacterium tuberculosis
Mol Microbiol
2002b
46
623
35

Mukamolova
GV
Yanopolskaya
ND
Kell
DB
et al.
On resuscitation from the dormant state of Micrococcus luteus
Anton Leeuw
1998b
73
237
43

Muñoz
P
Cruz
AF
Rodríguez-Créixems
M
et al.
Gram-negative bloodstream infections
Int J Antimicrob Ag
2008
32
Suppl 1
S10
14

Munteanu
D
Negru
A
Radulescu
M
et al.
Evaluation of bacterial translocation in patients with chronic HCV infection
Rom J Intern Med
2014
52
91
6

Murray
PR
Bennett
JE
Dolin
R
Blaser
MJ
The clinician and the microbiology laboratory
Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases
2015
Philadelphia
Saunders Elsevier

Mylotte
JM
Tayara
A
Blood cultures: clinical aspects and controversies
Eur J Clin Microbiol
2000
19
157
63

Nagalingam
NA
Lynch
SV
Role of the microbiota in inflammatory bowel diseases
Inflamm Bowel Dis
2012
18
968
84

Nagata
E
de Toledo
A
Oho
T
Invasion of human aortic endothelial cells by oral viridans group streptococci and induction of inflammatory cytokine production
Mol Oral Microbiol
2011
26
78
88

Narihiro
T
Kamagata
Y
Cultivating yet-to-be cultivated microbes: the challenge continues
Microbes Environ
2013
28
163
5

Natarajan
N
Pluznick
JL
From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology
Am J Physiol-Cell Ph
2014
307
C979
85

Neuman
Y
Cryptobiosis: a new theoretical perspective
Prog Biophys Mol Bio
2006
92
258
67

Nichols
D
Cahoon
N
Trakhtenberg
EM
et al.
Use of ichip for high-throughput in situ cultivation of ‘uncultivable’ microbial species
Appl Environ Microb
2010
76
2445
50

Nielsen
HH
Qiu
J
Friis
S
et al.
Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark
Eur J Neurol
2012
19
864
9

Nikkari
S
McLaughlin
IJ
Bi
W
et al.
Does blood of healthy subjects contain bacterial ribosomal DNA?
J Clin Microbiol
2001
39
1956
9

O'Mahony
SM
Clarke
G
Borre
YE
et al.
Serotonin, tryptophan metabolism and the brain-gut-microbiome axis
Behav Brain Res
2015
277
32
48

Ochoa-Repáraz
J
Mielcarz
DW
Begum-Haque
S
et al.
Gut, bugs, and brain: role of commensal bacteria in the control of central nervous system disease
Ann Neurol
2011
69
240
7

Ochoa-Repáraz
J
Mielcarz
DW
Ditrio
LE
et al.
Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis
J Immunol
2009
183
6041
50

Ogrendik
M
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial
Clin Ther
2009a
31
1754
64

Ogrendik
M
Rheumatoid arthritis is linked to oral bacteria: etiological association
Mod Rheumatol
2009b
19
453
6

Ogrendik
M
Antibiotics for the treatment of rheumatoid arthritis
Int J Gen Med
2013a
7
43
7

Ogrendik
M
Rheumatoid arthritis is an autoimmune disease caused by periodontal pathogens
Int J Gen Med
2013b
6
383
6

Oláh
A
Romics
L
Jr
Enteral nutrition in acute pancreatitis: a review of the current evidence
World J Gastroenterol
2014
20
16123
31

Owen
JL
Mohamadzadeh
M
Microbial activation of gut dendritic cells and the control of mucosal immunity
J Interf Cytok Res
2013
33
619
31

Owyang
C
Wu
GD
The gut microbiome in health and disease
Gastroenterology
2014
146
1433
6

Page
EE
Nelson
M
Kelleher
P
HIV and hepatitis C coinfection: pathogenesis and microbial translocation
Curr Opin HIV AIDS
2011
6
472
7

Pallen
MJ
Loman
NJ
Penn
CW
High-throughput sequencing and clinical microbiology: progress, opportunities and challenges
Curr Opin Microbiol
2010
13
625
31

Parracho
HM
Bingham
MO
Gibson
GR
et al.
Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children
J Med Microbiol
2005
54
987
91

Percival
SL
Hill
KE
Williams
DW
et al.
A review of the scientific evidence for biofilms in wounds
Wound Repair Regen
2012
20
647
57

Petersen
C
Round
JL
Defining dysbiosis and its influence on host immunity and disease
Cell Microbiol
2014
16
1024
33

Petriz
BA
Castro
AP
Almeida
JA
et al.
Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats
BMC Genomics
2014
15
511

Pflughoeft
KJ
Versalovic
J
Human microbiome in health and disease
Annu Rev Pathol
2012
7
99
122

Pham
VH
Kim
J
Cultivation of unculturable soil bacteria
Trends Biotechnol
2012
30
475
84

Postgate
JR
Viability measurements and the survival of microbes under minimum stress
Adv Microb Physiol
1967
1
1
23

Postgate
JR
Viable counts and viability
Methods Microbiol
1969
1
611
28

Postgate
JR
Death in Microbes and Macrobes
1976
Cambridge
Cambridge University Press

Power
SE
O'Toole
PW
Stanton
C
et al.
Intestinal microbiota, diet and health
Brit J Nutr
2014
111
387
402

Prajsnar
TK
Hamilton
R
Garcia-Lara
J
et al.
A privileged intraphagocyte niche is responsible for disseminated infection of Staphylococcus aureus in a zebrafish model
Cell Microbiol
2012
14
1600
19

Pretorius
E
Bester
J
Vermeulen
N
et al.
Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents
PlosOne
2014a
9
e85271

Pretorius
E
Kell
DB
Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases
Integr Biol
2014
6
486
510

Pretorius
E
Swanepoel
AC
Buys
AV
et al.
Eryptosis as a marker of Parkinson's disease
Aging
2014b
6
788
818

Pretorius
E
Vermeulen
N
Bester
J
et al.
A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy
Toxicol Mech Method
2013
23
352
9

Primas
H
Chemistry, Quantum Mechanics and Reductionism
1981
Berlin
Springer

Proal
AD
Albert
PJ
Marshall
TG
Nelson
KE
Autoimmune disease and the human metagenome
Metagenomics of the Human Body
2011
New York
Springer Science and Business Media

Proal
AD
Albert
PJ
Marshall
TG
et al.
Immunostimulation in the treatment for chronic fatigue syndrome/myalgic encephalomyelitis
Immunol Res
2013
56
398
412

Proal
AD
Albert
PJ
Marshall
TG
Inflammatory disease and the human microbiome
Discov Med
2014
17
257
65

Puddu
A
Sanguineti
R
Montecucco
F
et al.
Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes
Mediat Inflamm
2014
2014
162021

Puleo
F
Arvanitakis
M
Van Gossum
A
et al.
Gut failure in the ICU
Semin Respir Crit Care
2011
32
626
38

Puspita
DI
Kamagata
Y
Tanaka
M
et al.
Are uncultivated bacteria really uncultivable?
Microbes Environ
2012
27
356
66

Puspita
DI
Uehara
M
Katayama
T
et al.
Resuscitation promoting factor (Rpf) from Tomitella biformata AHU 1821(T) promotes growth and resuscitates non-dividing cells
Microbes Environ
2013
28
58
64

Qin
J
Li
Y
Cai
Z
et al.
A metagenome-wide association study of gut microbiota in type 2 diabetes
Nature
2012
490
55
60

Radajewski
S
Ineson
P
Parekh
NR
et al.
Stable-isotope probing as a tool in microbial ecology
Nature
2000
403
646
9

Ramírez
JH
Parra
B
Gutierrez
S
et al.
Biomarkers of cardiovascular disease are increased in untreated chronic periodontitis: a case control study
Aust Dent J
2014
59
29
36

Ratledge
C
Iron metabolism and infection
Food Nutr Bull
2007
28
S515
23

Rechner
AR
Kuhnle
G
Hu
H
et al.
The metabolism of dietary polyphenols and the relevance to circulating levels of conjugated metabolites
Free Radical Res
2002
36
1229
41

Renesto
P
Crapoulet
N
Ogata
H
et al.
Genome-based design of a cell-free culture medium for Tropheryma whipplei
Lancet
2003
362
447
9

Renko
J
Lepp
PW
Oksala
N
et al.
Bacterial signatures in atherosclerotic lesions represent human commensals and pathogens
Atherosclerosis
2008
201
192
7

Rhee
SH
Lipopolysaccharide: basic biochemistry, intracellular signaling, and physiological impacts in the gut
Intest Res
2014
12
90
5

Rinke
C
Schwientek
P
Sczyrba
A
et al.
Insights into the phylogeny and coding potential of microbial dark matter
Nature
2013
499
431
7

Robles-Alonso
V
Guarner
F
From basic to applied research: lessons from the human microbiome projects
J Clin Gastroenterol
2014
48
Suppl 1
S3
4

Rogler
G
Rosano
G
The heart and the gut
Eur Heart J
2014
35
426
30

Rolain
JM
Maurin
M
Mallet
MN
et al.
Culture and antibiotic susceptibility of Bartonella quintana in human erythrocytes
Antimicrob Agents Ch
2003
47
614
9

Ronco
C
Endotoxin removal: history of a mission
Blood Purif
2014
37
Suppl 1
5
8

Rooks
MG
Veiga
P
Wardwell-Scott
LH
et al.
Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission
ISME J
2014
8
1403
17

Rosenfeld
ME
Campbell
LA
Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis
Thromb Haemostasis
2011
106
858
67

Ross
R
Mills
S
Hill
C
et al.
Specific metabolite production by gut microbiota as a basis for probiotic function
Int Dairy J
2010
20
269
76

Sabatino
A
Regolisti
G
Brusasco
I
et al.
Alterations of intestinal barrier and microbiota in chronic kidney disease
Nephrol Dial Transpl
2014
DOI:10.1093/ndt/gfu287

Sacchi
P
Cima
S
Corbella
M
et al.
Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection
Dig Liver Dis
2015
47
218
25

Sahin
N
Gonzalez
JM
Iizuka
T
et al.
Characterization of two aerobic ultramicrobacteria isolated from urban soil and a description of Oxalicibacterium solurbis sp. nov
FEMS Microbiol Lett
2010
307
25
9

Saito
A
Rolfe
RD
Edelstein
PH
et al.
Comparison of liquid growth media for Legionella pneumophila
J Clin Microbiol
1981
14
623
7

Salipante
SJ
Roach
DJ
Kitzman
JO
et al.
Large-scale genomic sequencing of extraintestinal pathogenic Escherichia coli strains
Genome Res
2015
25
119
28

Salipante
SJ
Sengupta
DJ
Rosenthal
C
et al.
Rapid 16S rRNA next-generation sequencing of polymicrobial clinical samples for diagnosis of complex bacterial infections
PLoS One
2013
8
e65226

Salter
SJ
Cox
MJ
Turek
EM
et al.
Reagent and laboratory contamination can critically impact sequence-based microbiome analyses
BMC Biol
2014
12
87

Sánchez-Calvo
JM
García-Castillo
M
Lamas
A
et al.
Gut microbiota composition in cystic fibrosis patients: molecular approach and classical culture
J Cyst Fibros
2008
7
S50

Sandler
NG
Douek
DC
Microbial translocation in HIV infection: causes, consequences and treatment opportunities
Nat Rev Microbiol
2012
10
655
66

Sanz
Y
Moya-Pérez
A
Microbiota, inflammation and obesity
Adv Exp Med Biol
2014
817
291
317

Sato
J
Kanazawa
A
Ikeda
F
et al.
Gut dysbiosis and detection of ‘live gut bacteria’ in blood of Japanese patients with type 2 diabetes
Diabetes Care
2014
37
2343
50

Sato
S
Kiyono
H
Fujihashi
K
Mucosal immunosenescence in the gastrointestinal tract: a mini-review
Gerontology
2014

Sawa
T
The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response
J Intensive Care
2014
2
10

Sayin
SI
Wahlstrom
A
Felin
J
et al.
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist
Cell Metab
2013
17
225
35

Scanlan
PD
Buckling
A
Kong
W
et al.
Gut dysbiosis in cystic fibrosis
J Cyst Fibros
2012
11
454
5

Scheperjans
F
Aho
V
Pereira
PA
et al.
Gut microbiota are related to Parkinson's disease and clinical phenotype
Movement Disord
2015
30
350
8

Scher
JU
Abramson
SB
The microbiome and rheumatoid arthritis
Nat Rev Rheumatol
2011
7
569
78

Schnabl
B
Brenner
DA
Interactions between the intestinal microbiome and liver diseases
Gastroenterology
2014
146
1513
24

Schroeter
J
Wilkemeyer
I
Schiller
RA
et al.
Validation of the microbiological testing of tissue preparations using the BACTEC blood culture system
Transfus Med Hemoth
2012
39
387
90

Schulz
MD
Atay
C
Heringer
J
et al.
High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity
Nature
2014
514
508
12

Seksik
P
Rigottier-Gois
L
Gramet
G
et al.
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon
Gut
2003
52
237
42

Seringec
N
Guncu
G
Arihan
O
et al.
Investigation of hemorheological parameters in periodontal diseases
Clin Hemorheol Micro
2014
DOI:10.3233/CH-141892

Severance
EG
Gressitt
KL
Stallings
CR
et al.
Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia
Schizophr Res
2013
148
130
7

Severance
EG
Yolken
RH
Eaton
WW
Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling
Schizophr Res
2014
DOI:10.1016/j.schres.2014.06.027

Sharma
BR
Infection in patients with severe burns: causes and prevention thereof
Infect Dis Clin N Am
2007
21
745
59

Shaw
MK
Cell invasion by Theileria sporozoites
Trends Parasitol
2003
19
2
6

Sheedy
JR
Wettenhall
RE
Scanlon
D
et al.
Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome
In Vivo
2009
23
621
8

Sia
AK
Allred
BE
Raymond
KN
Siderocalins: siderophore binding proteins evolved for primary pathogen host defense
Curr Opin Chem Biol
2013
17
150
7

Singh
S
Eldin
C
Kowalczewska
M
et al.
Axenic culture of fastidious and intracellular bacteria
Trends Microbiol
2013
21
92
9

Soina
VS
Lysak
LV
Konova
IA
et al.
Study of ultramicrobacteria (nanoforms) in soils and subsoil deposits by electron microscopy
Eurasian Soil Sci
2012
45
1048
56

Steinberg
SM
Bacterial translocation: what it is and what it is not
Am J Surg
2003
186
301
5

Stevenson
BS
Eichorst
SA
Wertz
JT
et al.
New strategies for cultivation and detection of previously uncultured microbes
Appl Environ Microb
2004
70
4748
55

Stewart
EJ
Growing unculturable bacteria
J Bacteriol
2012
194
4151
60

Straub
RH
Cutolo
M
Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management
Arthritis Rheum
2007
56
399
408

Swank
GM
Deitch
EA
Role of the gut in multiple organ failure: bacterial translocation and permeability changes
World J Surg
1996
20
411
7

Syrjänen
J
Valtonen
VV
Iivanainen
M
et al.
Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients
Brit Med J
1988
296
1156
60

Tanaka
T
Kawasaki
K
Daimon
S
et al.
A hidden pitfall in the preparation of agar media undermines microorganism cultivability
Appl Environ Microb
2014
80
7659
66

Taneja
V
Arthritis susceptibility and the gut microbiome
FEBS Lett
2014
588
4244
9

Tang
WH
Wang
Z
Levison
BS
et al.
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
New Engl J Med
2013
368
1575
84

Tedeschi
GG
Bondi
A
Paparelli
M
et al.
Electron microscopical evidence of the evolution of corynebacteria-like microorganisms within human erythrocytes
Experientia
1978
34
458
60

Thaiss
CA
Zeevi
D
Levy
M
et al.
Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis
Cell
2014
159
514
29

The Integrative HMP (iHMP) Research Network Consortium
The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease
Cell Host Microbe
2014
16
276
89

Thwaites
GE
Gant
V
Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?
Nat Rev Microbiol
2011
9
215
22

Tojo
R
Suárez
A
Clemente
MG
et al.
Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis
World J Gastroenterol
2014
20
15163
76

Tomas-Barberan
F
Garcia-Villalba
R
Quartieri
A
et al.
In vitro transformation of chlorogenic acid by human gut microbiota
Mol Nutr Food Res
2014
58
1122
31

Touati
D
Iron and oxidative stress in bacteria
Arch Biochem Biophys
2000
373
1
6

Trøseid
M
Manner
IW
Pedersen
KK
et al.
Microbial translocation and cardiometabolic risk factors in HIV infection
AIDS Res Hum Retrov
2014
30
514
22

Tsujimoto
H
Ono
S
Mochizuki
H
Role of translocation of pathogen-associated molecular patterns in sepsis
Digest Surg
2009
26
100
9

Turnbaugh
PJ
Hamady
M
Yatsunenko
T
et al.
A core gut microbiome in obese and lean twins
Nature
2009
457
480
4

Turnbaugh
PJ
Ley
RE
Mahowald
MA
et al.
An obesity-associated gut microbiome with increased capacity for energy harvest
Nature
2006
444
1027
131

Vaarala
O
Human intestinal microbiota and type 1 diabetes
Curr Diabetes Rep
2013
13
601
7

Vajro
P
Paolella
G
Fasano
A
Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease
J Pediatr Gastr Nutr
2013
56
461
8

Valencia-Shelton
F
Loeffelholz
M
Nonculture techniques for the detection of bacteremia and fungemia
Future Microbiol
2014
9
543
59

van der Merwe
J
Prysliak
T
Perez-Casal
J
Invasion of bovine peripheral blood mononuclear cells and erythrocytes by Mycoplasma bovis
Infect Immun
2010
78
4570
8

van Duynhoven
J
Vaughan
EE
Jacobs
DM
et al.
Metabolic fate of polyphenols in the human superorganism
P Natl Acad Sci USA
2011
108
Suppl 1
4531
8

Varani
S
Stanzani
M
Paolucci
M
et al.
Diagnosis of bloodstream infections in immunocompromised patients by real-time PCR
J Infect
2009
58
346
51

Vartoukian
SR
Palmer
RM
Wade
WG
Strategies for culture of ‘unculturable’ bacteria
FEMS Microbiol Lett
2010
309
1
7

Vázquez-Castellanos
JF
Serrano-Villar
S
Latorre
A
et al.
Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals
Mucosal Immunol
2014
DOI:10.1038/mi.2014.107

Venkatesh
M
Mukherjee
S
Wang
H
et al.
Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4
Immunity
2014
41
296
310

Vila-Corcoles
A
Ochoa-Gondar
O
Rodriguez-Blanco
T
et al.
Evaluating clinical effectiveness of pneumococcal vaccination in preventing stroke: the CAPAMIS Study 3-year follow-up
J Stroke Cerebrovasc
2014
23
1577
84

Vincent
JL
Rello
J
Marshall
J
et al.
International study of the prevalence and outcomes of infection in intensive care units
JAMA
2009
302
2323
9

Vitry
MA
Hanot Mambres
D
Deghelt
M
et al.
Brucella melitensis invades murine erythrocytes during infection
Infect Immun
2014
82
3927
38

Vizcarra
JA
Wilson-Perez
HE
Espay
AJ
The power in numbers: gut microbiota in Parkinson's disease
Movement Disord
2015
30
296
8

Vogl
G
Plaickner
A
Szathmary
S
et al.
Mycoplasma gallisepticum invades chicken erythrocytes during infection
Infect Immun
2008
76
71
7

Votyakova
TV
Kaprelyants
AS
Kell
DB
Influence of viable cells on the resuscitation of dormant cells in Micrococcus luteus cultures held in an extended stationary phase: the population effect
Appl Environ Microb
1994
60
3284
91

Vujkovic-Cvijin
I
Dunham
RM
Iwai
S
et al.
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism
Sci Transl Med
2013
5
193
1

Walker
AW
Duncan
SH
Louis
P
et al.
Phylogeny, culturing, and metagenomics of the human gut microbiota
Trends Microbiol
2014
22
267
74

Wallet
F
Loiez
C
Herwegh
S
et al.
Usefulness of real-time PCR for the diagnosis of sepsis in ICU-acquired infections
Infect Disord Drug Targets
2011
11
348
53

Wang
Y
Chen
Y
Zhou
Q
et al.
A culture-independent approach to unravel uncultured bacteria and functional genes in a complex microbial community
PLoS One
2012c
7
e47530

Wang
Z
Klipfell
E
Bennett
BJ
et al.
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Nature
2011
472
57
63

Wang
Z
Zhang
L
Guo
Z
et al.
A unique feature of iron loss via close adhesion of Helicobacter pylori to host erythrocytes
PLoS One
2012b
7
e50314

Wang
ZW
Li
Y
Huang
LY
et al.
Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis
J Neurol
2012a
259
2527
37

Weinstein
MP
Current blood culture methods and systems: clinical concepts, technology, and interpretation of results
Clin Infect Dis
1996
23
40
6

Weinstock
GM
Genomic approaches to studying the human microbiota
Nature
2012
489
250
6

West
SA
Buckling
A
Cooperation, virulence and siderophore production in bacterial parasites
Proc R Soc B
2003
270
37
44

Wiest
R
Garcia-Tsao
G
Bacterial translocation (BT) in cirrhosis
Hepatology
2005
41
422
33

Wiest
R
Lawson
M
Geuking
M
Pathological bacterial translocation in liver cirrhosis
J Hepatol
2014
60
197
209

Wiest
R
Rath
HC
Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut
Best Pract Res Cl Ga
2003
17
397
425

Wikoff
WR
Anfora
AT
Liu
J
et al.
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites
P Natl Acad Sci USA
2009
106
3698
703

Williams
BB
Van Benschoten
AH
Cimermancic
P
et al.
Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine
Cell Host Microbe
2014
16
495
503

Williams
BL
Hornig
M
Buie
T
et al.
Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances
PLoS One
2011
6
e24585

Williams
BL
Hornig
M
Parekh
T
et al.
Application of novel PCR-based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances
MBio
2012
3
00261–11

Williams
TA
Foster
PG
Cox
CJ
et al.
An archaeal origin of eukaryotes supports only two primary domains of life
Nature
2013
504
231
6

Wilson
ML
Weinstein
MP
General principles in the laboratory detection of bacteremia and fungemia
Clin Lab Med
1994
14
69
82

Winter
SE
Thiennimitr
P
Winter
MG
et al.
Gut inflammation provides a respiratory electron acceptor for Salmonella
Nature
2010
467
426
9

Woese
CR
Fox
GE
Phylogenetic structure of the prokaryotic domain: the primary kingdoms
P Natl Acad Sci USA
1977
74
5088
90

Woese
CR
Kandler
O
Wheelis
ML
Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eucarya
P Natl Acad Sci USA
1990
87
4576
79

Xayarath
B
Freitag
NE
Optimizing the balance between host and environmental survival skills: lessons learned from Listeria monocytogenes
Future Microbiol
2012
7
839
52

Yamaguchi
M
Terao
Y
Mori-Yamaguchi
Y
et al.
Streptococcus pneumoniae invades erythrocytes and utilizes them to evade human innate immunity
PLoS One
2013
8
e77282

Yang
J
Feng
L
Ren
J
et al.
Correlation between the severity of periodontitis and coronary artery stenosis in a Chinese population
Aust Dent J
2013
58
333
8

Yarza
P
Spröer
C
Swiderski
J
et al.
Sequencing orphan species initiative (SOS): filling the gaps in the 16S rRNA gene sequence database for all species with validly published names
Syst Appl Microbiol
2013
36
69
73

Yatsunenko
T
Rey
FE
Manary
MJ
et al.
Human gut microbiome viewed across age and geography
Nature
2012
486
222
7

Young
D
Stark
J
Kirschner
D
Systems biology of persistent infection: tuberculosis as a case study
Nat Rev Microbiol
2008
6
520
8

Yu
RQ
Yuan
JL
Ma
LY
et al.
Probiotics improve obesity-associated dyslipidemia and insulin resistance in high-fat diet-fed rats
Zhongguo Dang Dai Er Ke Za Zhi
2013
15
1123
7

Zengler
K
Toledo
G
Rappe
M
et al.
Cultivating the uncultured
P Natl Acad Sci USA
2002
99
15681
6

Zhang
H
Liao
X
Sparks
JB
et al.
Dynamics of gut microbiota in autoimmune lupus
Appl Environ Microb
2014a
80
7551
60

Zhang
R
Lahens
NF
Ballance
HI
et al.
A circadian gene expression atlas in mammals: implications for biology and medicine
P Natl Acad Sci USA
2014b
111
16219
24

Zhang
Y
Yew
WW
Barer
MR
Targeting persisters for tuberculosis control
Antimicrob Agents Ch
2012
56
2223
30

Zhang
Y
Zou
Y
Ma
P
et al.
Identification of Mycoplasma suis MSG1 interaction proteins on porcine erythrocytes
Arch Microbiol
2014c
80
7551
60

Zhu
Y
Jameson
E
Crosatti
M
et al.
Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota
P Natl Acad Sci USA
2014
111
4268
73

Zimmermann
MB
Chassard
C
Rohner
F
et al.
The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire
Am J Clin Nutr
2010
92
1406
15

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.